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Abstract
Carotid artery stenting compared with endarterectomy in
patients with symptomatic carotid stenosis (International
Carotid Stenting Study): a randomised controlled trial
with cost-effectiveness analysis
Roland L Featherstone,1 Joanna Dobson,2 Jörg Ederle,1 David Doig,1
Leo H Bonati,1,3 Stephen Morris,4 Nishma V Patel4 and
Martin M Brown1*
1Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, University College
London, London, UK
2Department of Medical Statistics Unit, Faculty of Epidemiology and Population Health,
London School of Hygiene and Tropical Medicine, London, UK
3Department of Neurology and Stroke Centre, University Hospital Basel, Basel University,
Basel, Switzerland
4Department of Applied Health Research, University College London, London, UK
*Corresponding author martin.brown@ucl.ac.uk
Background: Carotid artery stenting (CAS) is an alternative to carotid endarterectomy (CEA) for the
treatment of carotid stenosis, but safety and long-term efficacy were uncertain.
Objective: To compare the risks, benefits and cost-effectiveness of CAS versus CEA for symptomatic
carotid stenosis.
Design: International, multicentre, randomised controlled, open, prospective clinical trial.
Setting: Hospitals at 50 centres worldwide.
Participants: Patients older than 40 years of age with symptomatic atheromatous carotid artery stenosis.
Interventions: Patients were randomly allocated stenting or endarterectomy using a computerised service
and followed for up to 10 years.
Main outcome measures: The primary outcome measure was the long-term rate of fatal or disabling
stroke, analysed by intention to treat (ITT). Disability was assessed using the modified Rankin Scale (mRS).
A cost–utility analysis estimating mean costs and quality-adjusted life-years (QALYs) was calculated over a
5-year time horizon.
Results: A total of 1713 patients were randomised but three withdrew consent immediately, leaving 1710
for ITT analysis (853 were assigned to stenting and 857 were assigned to endarterectomy). The incidence of
stroke, death or procedural myocardial infarction (MI) within 120 days of treatment was 8.5% in the CAS
group versus 5.2% in the CEA group (72 vs. 44 events) [hazard ratio (HR) 1.69, 95% confidence interval
(CI) 1.16 to 2.45; p= 0.006]. In the analysis restricted to patients who completed stenting, age independently
predicted the risk of stroke, death or MI within 30 days of CAS (relative risk increase 1.17% per 5 years of
age, 95% CI 1.01% to 1.37%). Use of an open-cell stent conferred higher risk than a closed-cell stent
(relative risk 1.92, 95% CI 1.11 to 3.33), but use of a cerebral protection device did not modify the risk.
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CAS was associated with a higher risk of stroke in patients with an age-related white-matter changes score
of 7 or more (HR 2.98, 95% CI 1.29 to 6.93; p= 0.011). After completion of follow-up with a median of
4.2 years, the number of patients with fatal or disabling stroke in the CAS and CEA groups (52 vs. 49), and
the cumulative 5-year risk did not differ significantly (6.4% vs. 6.5%) (HR 1.06, 95% CI 0.72 to 1.57;
p= 0.776). Stroke of any severity was more frequent in the CAS group (15.2% vs. 9.4% in the CEA group)
(HR 1.712, 95% CI 1.280 to 2.300; p< 0.001). There was no significant difference in long-term rates of
severe carotid restenosis or occlusion (10.8% in the CAS group vs. 8.6% in the CEA group) (HR 1.25, 95%
CI 0.89 to 1.75; p= 0.20). There was no difference in the distribution of mRS scores at 1-year, 5-year or final
follow-up. There were no differences in costs or QALYs between the treatments.
Limitations: Patients and investigators were not blinded to treatment allocation. Interventionists’
experience of stenting was less than that of surgeons with endarterectomy. Data on costs of managing
strokes were not collected.
Conclusions: The functional outcome after stenting is similar to endarterectomy, but stenting is associated
with a small increase in the risk of non-disabling stroke. The choice between stenting and endarterectomy
should take into account the procedural risks related to individual patient characteristics. Future studies should
include measurement of cognitive function, assessment of carotid plaque morphology and identification of
clinical characteristics that determine benefit from revascularisation.
Trial registration: Current Controlled Trials ISRCTN25337470.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 20.
See the NIHR Journal Library website for further project information. Further funding was provided by
the Medical Research Council, Stroke Association, Sanofi-Synthélabo and the European Union.
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Plain English summary
Narrowing of one of the carotid arteries in the neck by deposits of fat in the artery wall is a majorcause of stroke. The International Carotid Stenting Study (ICSS) compared two treatments to prevent
stroke resulting from this narrowing. The first was surgical treatment (endarterectomy), which removes
the fatty deposits altogether via an incision in the neck. The second was the newer treatment of carotid
stenting, in which a wire mesh tube (a stent) is inserted inside the narrowed artery after being threaded up
to the neck through the arteries in the leg via a puncture in the groin. The trial included 1713 patients
who had recently had a stroke or transient ischaemic attack (‘mini stroke’) caused by carotid narrowing,
at 50 centres in the UK, mainland Europe, Canada, Australia and New Zealand. Half the patients were
randomly assigned to stenting and half to surgery. ICSS showed that stenting avoids complications of
surgical incision in the neck, but caused more minor strokes at the time of the treatment than surgery.
The combination of procedural stroke or death was more frequent in the stenting group. During long-term
follow-up (median 4.2 years), the proportion of patients with fatal or disabling stroke was essentially
the same for both stenting and endarterectomy. Any stroke during follow-up was more frequent in the
stenting group. There were no differences in the costs of the two treatments. Therefore, endarterectomy
remains the treatment of choice for patients at higher risk with stenting, but stenting is an appropriate
treatment choice for patients if the risk of periprocedural stroke is low.
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Scientific summary
Background
Atherosclerotic stenosis of the carotid artery is a major cause of stroke. Carotid endarterectomy (CEA) has
been shown in previous trials to significantly reduce the risk of stroke in patients with symptomatic
atherosclerotic carotid stenosis. However, carotid artery stenting (CAS) is considered to be less invasive
than CEA and has advantages in terms of patient comfort because the procedure avoids an incision in the
neck and is conducted under local anaesthesia. At the time of the inception of the International Carotid
Stenting Study (ICSS), stenting was being widely adopted for the treatment of carotid stenosis on the basis
of case series in the absence of randomised trial evidence. ICSS was initiated to provide such evidence.
Objectives
The primary objective of ICSS was to compare the long-term rate of fatal or disabling stroke in
patients randomly allocated a treatment policy of referral for carotid stenting compared with referral for
carotid surgery.
Secondary analyses examined:
l short-term and long-term differences in mortality and morbidity related to treatment
l the short-term risk of cerebral ischaemia assessed by magnetic resonance imaging (MRI) after treatment
l predictors of the perioperative risks of treatment
l the rate of restenosis during follow-up
l differences in functional outcome during follow-up
l the cost-effectiveness of carotid stenting compared with surgery.
Methods
The ICSS was an international, multicentre, randomised controlled, open, prospective clinical trial
comparing carotid surgery with carotid stenting.
Participants
Patients of either sex over the age of 40 years with symptomatic atherosclerotic stenosis of the
carotid artery.
Inclusion criteria
l Symptomatic, extracranial, internal or bifurcation atheromatous carotid artery stenosis suitable for both
stenting and surgery, and deemed to require treatment.
l The severity of the stenosis of the randomised artery had to be at least 50% (as measured by the
North American Symptomatic Carotid Endarterectomy Trial method or non-invasive equivalent).
l Symptoms must have occurred in the 12 months before randomisation. It was recommended that the
time between symptoms and randomisation should be < 6 months, but patients with symptoms
between 6 months and 12 months could be included if treatment was indicated.
l The patient had to be clinically stable following their most recent symptoms.
l Patients could only be randomised if the investigator was uncertain which of the two treatments was
best for that patient at that time.
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Exclusion criteria
l Patients unable or unwilling to give informed consent or participate in follow-up.
l Patients who had previously had a major stroke with no useful recovery of function.
l Patients with a stenosis unsuitable for stenting prior to randomisation because of one or more of:
¢ tortuous anatomy proximal or distal to the stenosis
¢ presence of visible thrombus
¢ proximal common carotid artery stenotic disease
¢ pseudo-occlusion (‘string sign’).
l Patients not suitable for surgery owing to anatomical factors (e.g. high stenosis).
l Patients in whom it was planned to carry out coronary artery bypass grafting or other major surgery
within 1 month of carotid stenting or endarterectomy.
l Carotid stenosis caused by non-atherosclerotic disease (e.g. dissection, fibromuscular disease or
neck radiotherapy).
l Previous CEA or stenting in the randomised artery.
l Patients in whom common carotid artery surgery was planned.
l Patients medically not fit for surgery.
l Patients who had a life expectancy of < 2 years owing to a pre-existing condition (e.g. cancer).
Randomisation
Patients were randomly allocated in equal proportions to endarterectomy or stenting. Randomisation
was performed by a telephone call or fax to a computerised service provided by the Oxford Clinical Trials
Service Unit and was stratified by centre with minimisation of the main risk factors balanced between
the arms.
Interventions
Endarterectomy was carried out as soon as possible after randomisation by a consultant surgeon approved
by the accreditation committee, using procedures standard at the centre.
Stenting was carried out as soon as possible after randomisation by an approved consultant interventionist
using an approved stent. A cerebral protection system was used whenever the operator thought that one
could be safely deployed.
Data collected at baseline
Baseline data collected at randomisation included demographic data, medical risk factors, symptoms and
an assessment of disability using the modified Rankin Scale (mRS), antiplatelet therapy and blood pressure,
films and reports of pre-randomisation brain imaging, and the results of duplex ultrasound (DUS).
Follow-up
Patients were followed up by a neurologist or a stroke physician at 30 days after treatment, 6 months after
randomisation and, then, annually. At each visit, levels of stroke-related disability were assessed using the
mRS and any outcome events were notified to the Central Trial Office. A DUS of the carotid arteries was
performed at each follow-up visit. In addition to the clinical data, patients were asked to complete a
European Quality of Life-5 Dimensions-3 level response (EQ-5D-3L™) questionnaire to assess health-related
quality of life at baseline and each follow-up. Utility values calculated from the EQ-5D-3L questionnaire
responses were used to calculate quality-adjusted life-years (QALYs) for every patient. Patients were
followed up to the end of 2011 (a maximum of 10 years after randomisation).
SCIENTIFIC SUMMARY
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Resource use and costs
For every patient, the cost of the index procedure and the cost of follow-up were calculated using
resource-use data collected prospectively. The former included: surgeon and radiologist time; operating
theatre time, including nursing staff, drugs, consumables and overheads; anaesthesia; materials and
devices, including stents, shunts, patches, cerebral protection devices, catheters, wires and sheaths; and
length of hospital stay in the intensive care unit (ICU) and inpatient ward. The latter included additional
carotid artery procedures; complications within 30 days of index procedure [fatal and non-fatal myocardial
infarction (MI), severe haematoma and disabling cranial nerve palsy]; imaging tests; drug treatment; and
non-disabling, disabling and fatal strokes. Length of stay in the ICU was not collected for individual
patients, but mean values were collected by centre. From these data we assumed that where patients were
admitted to the ICU post-operatively, it was for 1 day.
Results
Between May 2001 and October 2008, 1713 patients from 50 centres in the UK, mainland Europe, Australia,
New Zealand and Canada were randomised. Patients were followed up for a median of 4.2 years and a
maximum of 10 years after randomisation, amounting to 7355 patient years of follow-up.
Short-term outcomes
In the intention-to-treat (ITT) analysis, the risk of stroke, death or procedural MI between randomisation and
120 days was significantly higher in patients in the stenting group than in patients in the endarterectomy group
(8.5% vs. 5.1%), representing an estimated 120-day absolute risk difference of 3.3% [95% confidence interval
(CI) 0.9% to 5.7%] with a hazard ratio (HR) in favour of surgery of 1.69 (95% CI 1.16 to 2.45, log-rank
p= 0.006). There was no significant difference in the rate of disabling stroke or death between groups (4.0%
in the stenting group vs. 3.2% in the endarterectomy group). The observed treatment effect was largely driven
by the higher number of non-disabling strokes in the stenting group. Cranial nerve palsies were almost
completely avoided by stenting [risk ratio (RR) 0.02, 95% CI 0.00 to 0.16; p< 0.0001). There were also fewer
haematomas in the stenting group than in the endarterectomy group (RR 0.59, 95% CI 0.38 to 0.93;
p= 0.0197). Stenting was associated with a higher risk of stroke within 30 days of treatment compared with
endarterectomy in patients with an age-related white-matter changes (ARWMC) score on baseline brain
imaging of 7 or more (HR for any stroke 2.98, 95% CI 1.29 to 6.93; p= 0.011; HR for non-disabling stroke
6.34, 95% CI 1.45 to 27.71; p= 0.014), but there was no risk difference in patients with an ARWMC score of
< 7. In a separate analysis restricted to ICSS patients who were randomised to and completed stenting
treatment, age was an independent predictor of the risk of stroke, MI or death within 30 days of CAS (relative
risk increase 1.17% per 5 years of age, 95% CI 1.01% to 1.37%), as were a right-sided procedure (RR 0.54,
95% CI 0.32 to 0.91), aspirin and clopidogrel in combination prior to CAS (RR 0.59, 95% CI 0.36 to 0.98),
smoking status and the severity of index event. The use of an open-cell stent conferred higher risk than use of
a closed-cell stent (RR 1.92, 95% CI 1.11 to 3.33), but the use of a cerebral protection device did not modify
the risk. In a separate multivariable analysis restricted to ICSS patients who were randomised to and completed
endarterectomy, only diastolic blood pressure at baseline was a significant predictor of the risk of stroke, MI or
death within 30 days of CEA. Independent risk factors modifying the risk of cranial nerve palsy after CEA
in a multivariate analysis were cardiac failure (RR 2.66, 95% CI 1.11 to 6.40), female sex (RR 1.80, 95% CI
1.02 to 3.20), and the degree of contralateral carotid stenosis and time from randomisation to treatment
> 14 days (RR 3.33, 95% CI 1.05 to 10.57). The risk of haematoma after CEA was increased in women,
by the prescription of anticoagulant drugs pre procedure and in patients with atrial fibrillation.
Magnetic resonance imaging substudy findings
A total of 231 patients had MRI before and after treatment. Sixty-two (50%) of 124 patients in the
stenting group and 18 (17%) of 107 patients in the endarterectomy group had at least one new ischaemic
lesion detected on post-treatment MRI performed a median of 1 day after treatment (adjusted odds ratio
5.21, 95% CI 2.78 to 9.79; p< 0.0001).
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Primary outcome
In the ITT analysis, the primary outcome event, fatal or disabling stroke between randomisation and end of
follow-up, occurred in 52 patients in the stenting group, corresponding to a cumulative 5-year risk of
6.4%, and in 49 patients in the endarterectomy group (5-year risk of 6.5%), without any evidence for a
difference in time to first occurrence of an event (HR 1.06, 95% CI 0.72 to 1.57; p= 0.76).
Other long-term outcomes
In the ITT analysis, any stroke (5-year risks of 15.2% vs. 9.4%) (HR 1.71, 95% CI 1.28 to 2.30; p= 0.0003),
as well as the combination of any procedural stroke, procedural death or ipsilateral stroke during follow-up
(11.8% vs. 7.2%) (HR 1.72, 95% CI 1.24 to 2.39; p= 0.001), occurred significantly more often in the
stenting group. However, there was no difference in functional outcome between the groups as assessed
by the distribution of mRS scores at 1-year follow-up, 5-year follow-up or at the end of follow-up.
A total of 737 (98.0%) patients in the stenting group and 793 (97.8%) in the endarterectomy group were
followed up with carotid ultrasound for a median of 4.0 years after treatment. There was no significant
difference in long-term rates of severe carotid restenosis (≥ 70%) or occlusion, which occurred in
72 patients in the stenting group (5-year risk of 10.8%) and in 62 patients in the endarterectomy group
[5-year risk 8.6% (HR 1.25, 95% CI 0.89 to 1.75; p= 0.20)].
In the per-protocol analysis of events occurring more than 30 days after completed treatment up to the
end of follow-up, there was no significant difference in the rates of ipsilateral stroke in the territory of
the treated artery (4.7% vs. 3.4%) (HR 1.29, 95% CI 0.74 to 2.24; p= 0.36). However, stroke of any
severity occurred more often after stenting (8.9% vs. 5.8%) (HR 1.53, 95% CI 1.02 to 2.31; p= 0.039).
This difference was largely attributable to stroke occurring in the territory of the contralateral carotid artery
or the vertebrobasilar circulation among patients treated with stents, and the majority of these strokes
were non-disabling.
Cost–utility analysis
There were no differences in costs or QALYs between the treatments. Mean costs per patient were £7351
(95% CI £6786 to £7915) in the stenting group (n= 853) and £6762 (95% CI £6154 to £7369) in the
endarterectomy group (n= 857). Mean QALYs per patient were 3.247 in the stenting group (95% CI
3.160 to 3.333) and 3.228 in the endarterectomy group (95% CI 3.150 to 3.306). There were no
differences in adjusted costs between groups (mean incremental costs for stenting vs. endarterectomy
£537, 95% CI –£238 to £1312) or adjusted outcomes (mean QALYs gained –0.010, 95% CI –0.117 to
0.097). The incremental net monetary benefit for stenting compared with endarterectomy was not
significantly different from zero at a maximum willingness to pay for a QALY of £20,000 (mean –£723,
95% CI –£3134 to £1670). Sensitivity analyses showed little uncertainty in these findings.
Conclusions
The functional outcome of patients with symptomatic carotid stenosis treated by stenting is similar to
endarterectomy. CAS has a higher short-term (periprocedural) risk than CEA in terms of stroke but a lower
rate of severe haematoma and it avoids injury to cranial nerves during endarterectomy. The additional
short-term risk associated with CAS is largely attributable to non-disabling strokes. More extensive
white-matter changes on baseline brain imaging and older age of the patient increase the procedural
risks of stenting. The primary analysis of the trial showed that stenting is equivalent to endarterectomy in
preventing fatal or disabling stroke up to 10 years after treatment. Severe restenosis or occlusion of the
treated carotid artery was rare, with no difference between treatment groups. Stenting also appeared
to be as effective as endarterectomy in preventing ipsilateral stroke occurring during follow-up after the
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30-day procedural period. Stenting and endarterectomy had similar costs (index procedure costs, follow-up
costs and total costs) and outcomes (utility values, QALYs). This was despite the finding in the trial of
higher rates of non-disabling strokes in the stenting group. Comprehensive sensitivity analyses showed
little uncertainty in this finding. Non-significant differences in utility values and QALYs mirror differences in
mRS scores and all-cause mortality found in the trial.
Implications for health care
The data from ICSS show that stenting is a reasonable alternative to endarterectomy, especially if
there are features suggesting that the risk of procedural stroke with stenting is likely to be similar or lower
than that of endarterectomy (e.g. younger age or less than average severity of white-matter disease).
Such patients should be offered stenting after informed consent giving full consideration of the overall
periprocedural risks in the relevant groups. In addition to taking into account clinical and imaging features,
treatment decisions should take into account patient preferences with reference to the differing nature of
the risks with the two procedures. The findings of ICSS mean that there is no reason to prefer either
stenting or endarterectomy on economic grounds; other factors should be taken into account when
deciding which option to use to treat patients with symptomatic carotid stenosis.
Implications for research
Given the effect of stenting on silent infarction noted in ICSS–MRI substudy, measurement of cognitive
function might be an important part of any future study of stenting and/or CEA. Another important area
for future studies is identifying the clinical characteristics of patients that determine how likely they are to
benefit from revascularisation in the context of optimised medical therapy.
Trial registration
Current Controlled Trials ISRCTN25337470.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. Further funding was provided by the Medical Research Council, Stroke
Association, Sanofi-Synthélabo and European Union.
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Chapter 1 Introduction
Background
Stroke is the major cause of acquired adult physical disability and is responsible for 12% of all deaths in the
UK. In Europe alone, there are approximately one million new cases of stroke a year. Atherosclerotic stenosis
of the carotid artery is an important cause of stroke, which may be heralded by a transient ischaemic attack
(TIA) or minor stroke, which recovers without causing serious disability. The risk of recurrent stroke in
recently symptomatic patients with severe carotid stenosis is as high as 28% over 2 years. The European
Carotid Surgery Trial and the North American Symptomatic Carotid Endarterectomy Trial (NASCET)
demonstrated that this risk was reduced significantly by carotid endarterectomy (CEA) compared with best
medical treatment alone.1–3 Carotid surgery has, therefore, become a standard treatment for these patients.
However, the trials showed a significant risk of stroke or death resulting from surgery of between 6% and
8%. Surgery also caused significant morbidity from myocardial infarction (MI) during the general anaesthetic
used in most centres and minor morbidity, including cranial nerve palsy and wound haematoma, from
the incision.
The potential benefit of endovascular treatment (angioplasty with or without stenting) as an alternative to
CEA was first highlighted by the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS).4
This trial showed that endovascular treatment largely avoided the main complications of the endarterectomy
incision (namely cranial nerve injury and severe haematoma). However, the rate of stroke or death within
30 days after treatment was high in both groups. Since completion of CAVATAS, stenting has largely
replaced angioplasty, and stents and protection devices specifically designed for the carotid artery have
been introduced.
At the time of the inception of the International Carotid Stenting Study (ICSS), stenting was a new
method of treating carotid stenosis, which had evolved from the technique of percutaneous transluminal
angioplasty. Stenting avoids some of the hazards of surgery and has become an established treatment for
peripheral and coronary artery stenosis. Stenting is considered less invasive than CEA and has advantages in
terms of patient comfort, because the procedure avoids an incision in the neck and is usually conducted
under local anaesthesia. Hospital stay need only be for 24 hours after treatment if uncomplicated. When
given the choice, stenting is preferred by many patients. However, stenting does not remove the
atheromatous plaque, has not been shown to prevent stroke and might have an unacceptable incidence
of restenosis.
Rationale
It would have been inappropriate to use the results of CAVATAS to propose the widespread introduction
of percutaneous transluminal angioplasty for the treatment of carotid stenosis as an alternative to surgery,
because the 95% confidence interval (CI) surrounding the 10% risk of any stroke within 30 days of
treatment in the surgical and angioplasty groups was ± 5%. Nevertheless, the results supported the need
for further randomised studies. The interventional technique used to treat carotid stenosis evolved
during CAVATAS, from the use of simple inflatable balloon catheters at the beginning of the trial to the
increasing use of stenting towards the end of the trial. Initially, stents were used only as a secondary
procedure for inadequate results or complications of treatment after full balloon inflation. The desire to
prevent these complications and superior early results in stented patients led to the increasing use of the
technique of primary stenting, in which the intention is to deploy a stent in every patient before dilatation
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(but after pre dilatation if required to allow the atraumatic passage of the stent) of the artery.5 Primary
stenting is now accepted as best interventional practice6 and has become the radiological technique of
choice for carotid stenosis, replacing balloon angioplasty. ICSS was initiated to provide randomised trial
evidence on whether or not carotid artery stenting (CAS) was as effective as CEA in preventing recurrent
stroke that is associated with symptomatic carotid artery stenosis.
Potential risks and benefits
Both surgical endarterectomy and stenting carry a risk of causing a stroke at the time of the treatment.
Previous trials showed a significant risk of stroke or death at the time of surgery or stenting of between
6 and 10 in every 100 patients. However, patients were randomised to the study because the risk of
strokes resulting from surgical or stenting treatment was believed to be less than leaving the carotid artery
narrowing untreated. The majority of major strokes after carotid percutaneous transluminal angioplasty are
the result of dissection of the carotid artery at the time of balloon inflation with subsequent thrombosis.
It is believed that stenting is safer than simple balloon angioplasty because embolisation, dissection and
closure of the carotid artery are less likely to occur.5,6 The subgroup analysis of stented patients in
CAVATAS was consistent with this suggestion. The adverse consequences of dissection are minimised
because the stent maintains laminar flow across the stenosis and seals the site of dissection, preventing a
free intimal flap. In addition, the stent mesh limits the size of any thrombus or atheromatous debris that
may be dislodged from the plaque at the time of dilatation of the artery. Superior dilatation achieved by
stenting compared with balloon angioplasty may also reduce the rate of stroke in the early post-treatment
period. In the coronary circulation, stenting has been shown to produce superior outcomes compared with
balloon angioplasty.7,8 Individual case series suggested that carotid stenting has a similar rate of procedural
stroke to that of carotid surgery.5,6,9
Surgery also carries a risk of perioperative MI. Approximately 1 in 10 patients has temporary tongue or
facial weakness as a result of cranial nerve palsy. A large blood clot (haematoma) may form at the site of
incision, which may require removal. Surgery results in a permanent scar in the neck. Angiography and
stenting may also result in bruising or haematoma at the site of injection (usually in the groin) and can
cause temporary discomfort or pain in the neck. There is a small risk of allergic reactions to the contrast
reagent used during angiography.
Although acceptable safety at the time of stenting had been suggested by the case series and registry
data, at the time ICSS was initiated, stenting had not been subjected to a randomised trial in comparison
with conventional surgical treatment and had not been demonstrated to prevent stroke, which is the aim
of treatment.10 Stenting does not remove the atheromatous plaque and stents may stimulate neointimal
hyperplasia. In the long term, it is possible that the rate of restenosis would be greater after stenting than
after carotid surgery, which could well result in an unacceptable rate of long-term stroke recurrence. There
was, therefore, an important need to establish the efficacy of carotid stenting in comparison to surgery at
a time when the technique was being widely introduced without adequate trial-based evidence for its
safety and effectiveness.
INTRODUCTION
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Chapter 2 Methods
Objective
The objective of ICSS was to compare the risks, benefits and cost-effectiveness of a treatment policy of
referral for carotid stenting compared with referral for carotid surgery.
Design
The ICSS was an international, multicentre, randomised controlled, open, prospective clinical trial
comparing carotid surgery with carotid stenting. The trial was approved by the Northwest Multicentre
Research Committee in the UK and by local ethics committees outside the UK. The full version of the
protocol is available at www.cavatas.com.11
Participants
Patients of either sex over the age of 40 years with symptomatic atherosclerotic stenosis of the carotid artery
were included in the trial. The consent form and patient information form are shown in Appendices 1 and 2,
respectively. The inclusion and exclusion criteria are outlined below.
Inclusion criteria
l Symptomatic, extracranial, internal or bifurcation atheromatous carotid artery stenosis suitable for both
stenting and surgery, and deemed by the randomising clinician to require treatment.
l The severity of the stenosis of the randomised artery should be at least 50% (as measured by the
NASCET method or non-invasive equivalent).
l Symptoms must have occurred in the 12 months before randomisation. It was recommended that the
time between symptoms and randomisation should be < 6 months, but patients with symptoms
occurring between 6 months and 12 months could be included if the randomising physician considered
that treatment was indicated.
l The patient had to be clinically stable following their most recent symptoms attributable to the
stenotic vessel.
l Patients had to be willing to have either treatment, be able to provide informed consent and be willing
to participate in follow-up.
l Patients had to be able to undergo their allocated treatment as soon as possible after randomisation.
l Any patient > 40 years of age could be included.
l Patients could only be randomised if the investigator was uncertain which of the two treatments was
best for that patient at that time.
Exclusion criteria
l Patients refusing either treatment.
l Patients unable or unwilling to give informed consent.
l Patients unwilling or unable to participate in follow-up for whatever reason.
l Patients who had previously had a major stroke with no useful recovery of function within the territory
of the treatable artery.
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l Patients with a stenosis that was known to be unsuitable for stenting prior to randomisation because
of one or more of:
¢ tortuous anatomy proximal or distal to the stenosis
¢ presence of visible thrombus
¢ proximal common carotid artery stenotic disease
¢ pseudo-occlusion (‘string sign’).
l Patients not suitable for surgery owing to anatomical factors (e.g. high stenosis, rigid neck).
l Patients in whom it was planned to carry out coronary artery bypass grafting or other major surgery
within 1 month of carotid stenting or endarterectomy.
l Carotid stenosis caused by non-atherosclerotic disease (e.g. dissection, fibromuscular disease or
neck radiotherapy).
l Previous CEA or stenting in the randomised artery.
l Patients in whom common carotid artery surgery was planned.
l Patients medically not fit for surgery.
l Patients who had a life expectancy of < 2 years owing to a pre-existing condition (e.g. cancer).
Interventions
Stenting protocol
Stenting was carried out as soon as possible after randomisation using percutaneous transluminal
interventional techniques from the femoral, brachial or common carotid artery by a designated interventional
consultant using an appropriate stent. A cerebral protection system was used whenever the operator
thought that one could be safely deployed. Stents and other devices used in the trial had to be Conformité
Européenne (CE) marked and approved by the steering committee.
Pre-medication was at the discretion of the interventionist, although the protocol recommended the
combination of aspirin and clopidogrel as the antiplatelet regime of choice to cover the period of stenting
and for a minimum of 4 weeks afterwards. Intra-procedural heparin was mandatory at a dose determined
by the operator; post-procedural heparin could be given according to clinical requirements.
The trial protocol stated that atropine, or a similar agent, must be administered prior to stent deployment
to counteract any effects on the carotid artery baroreceptors, which could lead to severe bradycardia
or asystole.
Angiographic images showing the stenosis at its most severe prior to stenting and the same view and
any other view that demonstrated the maximum residual stenosis after stenting were collected by the
trial office.
Details of the procedure, including all periprocedural complications, drug therapy and devices used in the
procedure, were reported on the stenting and cerebral protection technical data sheet which was returned
to the trial central office.
Endarterectomy protocol
Endarterectomy was carried out as soon as possible after randomisation by a designated consultant
surgeon. It was carried out using whichever procedures were standard at the individual centre, including
the use of local or general anaesthesia, shunts or patches as required by the operating surgeon. Standard
or eversion endarterectomy could be performed. Details of the procedure, including all periprocedural
complications, drug therapy and type of endarterectomy performed, were reported on the surgery
technical data sheet which was returned to the trial central office.
METHODS
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Approval of surgeons and interventionists, and credentialing
of less-experienced operatives
An accreditation committee decided if surgeons and interventionists at enrolling centres had the appropriate
experience and expertise to join the study. Surgeons and interventionists were expected to show a stroke and
death rate within 30 days of treatment, consistent with the centres in the European Carotid Surgery Trial who
had an average rate of 7.0% with a 95% CI of 5.8% to 8.3%.1 Surgeons were expected to have performed a
minimum of 50 carotid operations with a minimum annual rate of at least 10 cases per year. Interventionists
were expected to have performed a minimum of 50 stenting procedures, of which at least 10 should have
been in the carotid territory. Centres that had little or no experience of carotid stenting were allowed to join
ICSS for a probationary period in order to gain the minimum experience of 10 carotid stenting procedures
required to join the trial fully. Stenting procedures carried out during the probationary period were proctored
by an experienced carotid interventionist appointed by the trial steering committee, until the proctor was
satisfied that the interventionist(s) at the centre could satisfactorily carry out procedures unproctored.
Probationary interventionists became fully enrolled in ICSS when the proctor was satisfied that the
interventionist could perform procedures unsupervised and the interventionist had 10 or more successfully
completed cases in the trial, with an acceptable complication rate.
Reporting of suspected problems with surgical or stenting
techniques at individual centres
The database manager at the trial office monitored periprocedural outcome events, and if there were
two consecutive deaths or three consecutive major events at a single centre within 30 days of treatment in
the same arm of the study, then assessment of the events was triggered. A blinded assessment of the
relevant outcome events was submitted by the central office to the chairman of the data monitoring
committee who had the power to recommend further action, such as suspending randomisation at the
centre. A cumulative major event or death rate of more than 10% over 20 cases would also trigger careful
assessment of the relevant outcome events.
Data collected at baseline
Baseline data collected at randomisation included demographic data; existing medical risk factors;
neurological symptoms and an assessment of disability using the modified Rankin Scale (mRS); current
antiplatelet therapy and blood pressure; and films and reports of pre-randomisation brain imaging and the
results of duplex ultrasound (DUS).
Randomisation
Randomisation was performed by a telephone call or fax to a computerised service provided by the
Oxford Clinical Trials Service Unit. It was stratified by centre with minimisation of the main risk factors
and balanced between the arms. Patients who needed treatment of both carotid arteries could only be
randomised for the carotid artery to be treated first. Two patients were randomised at the Service Unit by
coin toss when the computerized service was not available.
Follow-up
Patients were followed up by a neurologist or a physician interested in stroke, who was not involved in the
revascularisation procedure but who was not masked to group assignment, at the participating centres
at 30 days after treatment, 6 months after randomisation and, then, annually after randomisation.
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At each visit, levels of stroke-related disability were assessed using the mRS and any relevant outcome
events notified to the central trial office. DUS examinations of the carotid arteries were carried out
at each follow-up visit at centres with available facilities. Bilateral peak systolic and end diastolic velocities
in the internal carotid artery and the peak systolic velocity in the common carotid artery were recorded.
The data were collected on a follow-up form and an ultrasound report form (see Appendices 3 and 4),
which were returned to the central trial office where the data were entered into a Microsoft Access
(Microsoft Corporation, Redmond, WA, USA) database. In addition to the clinical data, patients
were asked to complete a EuroQol European Quality of Life-5 Dimensions – 3 level response (EQ-5D-3L™)
questionnaire (see www.euroqol.com) to assess quality of life and health status at baseline, after stenting
or surgery at 1 month, and then at 6-month and annual follow-up visits.
Patients were followed up to the end of the trial in 2011 (a maximum of 10 years after randomisation).
Patients reaching their 5-year follow-up before the end of the trial were asked if they were willing to carry
on with follow-up, in which case they continued with annual follow-up until the end of the trial.
Outcomes
The following events were collected and analysed as trial outcome events:
l any stroke or death
l TIA
l MI within 30 days of treatment
l cranial nerve palsy within 30 days of treatment
l haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay
l stenosis ≥ 70% or occlusion during follow-up
l further treatment of the randomised artery by interventional radiology techniques or surgery after the
initial attempt
l quality of life, health status and health service costs.
Outcome events included in the safety analysis or primary outcome (stroke, MI within 30 days of treatment,
death) were documented in detail by the investigating centre, censored after receipt at the central office to
remove clues as to the treatment allocated, and then adjudicated by a neurologist at the central office and
by an independent external neurologist. If the external neurologist’s adjudication differed from the central
office, a third independent neurologist reviewed the event and the majority opinion prevailed. The major
event and death forms are shown in Appendices 5 and 6.
Centres were asked to supply the following information for adjudication, whenever possible:
l a report of the event using the standard trial case report form
l a film copy of a computerised tomography (CT) or magnetic resonance imaging (MRI) brain scan as
soon as possible after the event, together with a film copy of the pre-randomisation scan (if done) and
a report of the event
l copies of discharge summaries, death certificates and post-mortem results (if relevant).
Disability after stroke and cranial nerve palsy was assessed 30 days after treatment or at onset using the
mRS. Duration of symptoms was recorded and outcome events were classified as disabling if the mRS
score was 3 or more at 1 month. If the patient was not seen at exactly 30 days after onset of the event,
the investigator was asked to estimate the 30-day mRS.
The degree of carotid stenosis during follow-up was determined in the study central office based on flow
velocity data using pre-defined criteria,12 masked to treatment allocation and date of ultrasound follow-up.
Results of carotid imaging studies ordered outside regular follow-up at the discretion of the treating
METHODS
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clinicians (e.g. for recurrent symptoms) were also included. The main outcome event of the restenosis
analysis was defined as any severe (≥ 70%) residual or recurrent stenosis, or occlusion of the carotid artery
during follow-up. No correction was made for the presence of a stent when measuring stenosis severity.
Statistical methods
All analyses were conducted according to the statistical analysis plan for the short-term (safety) analysis or
the long-term analysis (see Appendix 7), which provides a detailed and comprehensive description of the
main, pre-planned analyses for the study. Analyses were performed with Stata statistical software version
12.1 or earlier (StataCorp LP, College Station, TX, USA), except for the MRI substudy and the study on the
effect of white-matter lesions on periprocedural stroke, which used SPSS statistical software version 17
(SPSS Inc., Chicago, IL, USA) and version 21 (IBM Corp., Armonk, NY, USA), respectively.
The main features of the analysis plan are summarised below.
The Consolidated Standards of Reporting Trials (CONSORT) flow diagram is used to summarise
representativeness of the study sample and patient throughput (see Figure 1). Baseline characteristics are
presented by treatment group with continuous variables presented with means and standard error.
The analyses compare the treatment groups with respect to the length of time before treatment failure
(i.e. occurrence of an outcome event) by means of the Mantel–Haenszel chi-squared test and Kaplan–Meier
survival curves with a two-sided p-value of 0.05 (5% level) used to declare statistical significance with a
95% CI reported throughout. Secondary analyses compare the proportions of outcome events within
30 days of treatment. All analyses are adjusted for centre and pre-determined risk factors. Subgroup
analyses examine risk factors for outcome events.
Cox proportional hazard models were used to calculate the hazard ratio (HR) and 95% CI with
endarterectomy as the reference group using all available follow-up data. Log-rank tests were used to
compare the two survival curves. Censoring was assumed to be non-informative.
As the restenosis outcome was interval-censored it was instead analysed using a generalised non-linear
model which assumes proportional hazards and whose treatment effect parameter estimate can be
interpreted as a log-HR. The treatment effect p-value for the restenosis outcome was calculated using a
likelihood ratio test. Life-table analyses were used to estimate the cumulative incidences of restenosis
at 1 year and 5 years after treatment.
Interaction tests were performed to investigate whether or not the relative treatment effect for the
pre-defined primary long-term outcome, as well as for procedural stroke or death or ipsilateral stroke
during follow-up, differed across various patient groups. Functional ability at the final follow-up or at
death was compared between treatment groups across the entire range of the mRS at 1-year and
5-year follow-up using the permutation test described by Howard et al.13 Drug treatments and blood
pressure at 1-year and 5-year follow-up were compared using chi-squared tests and t-tests at each time
point, respectively.
Sample size (original and revised)
At the commencement of recruitment in 2001 we planned to recruit 2000 patients, but this was revised
shortly after the start of the trial in 2003 to 1500 in response to the initial funding period and taking
into account the observed recruitment rate to that date. For 1500 patients, the 95% CI was the observed
difference ± 3.0 percentage points for the outcome measure of 30-day stroke, MI and death rate and
± 3.3 percentage points for the outcome measure of death or disabling stroke over 3 years’ follow-up.
DOI: 10.3310/hta20200 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 20
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Featherstone et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
The difference detectable with power 80% was 4.7 percentage points for 30-day outcome and
5.1 percentage points for survival free of disabling stroke. Similar differences were detectable for secondary
outcomes. In 2007, the steering committee modified the protocol to emphasise that the sample size of
1500 patients should reflect only patients recruited at experienced centres, to ensure that the study would
be adequately powered to compare outcomes of stenting performed by experienced interventionists with
endarterectomy. An extension of funding was therefore obtained to allow the recruitment of a total of
1700 patients, anticipating that 200 of these would come from centres with probationary investigators.
Protocol amendments
The major amendments to the protocol during the course of the trial are detailed in Appendix 8. In brief,
in addition to the modifications to the sample size described above, in 2003, clarification of the rules
governing proctoring of probationary centres and the maximum permissible delays between symptoms and
randomisation were added to the protocol. In 2007, an amendment was made to state that data from
patients enrolled at probationary centres would be analysed separately from data from fully enrolled
experienced centres. Subsequently, the steering committee decided after completion of recruitment and
initial analysis of the results that the data from probationary and fully enrolled centres should be analysed
together, because there was no significant difference in the results (indeed the results were slightly better
at probationary centres).
The International Carotid Stenting Study–magnetic resonance
imaging substudy: symptomatic and asymptomatic ischaemic
and haemorrhagic brain injury following protected and
unprotected stenting versus endarterectomy
Clinical follow-up of patients in ICSS was not masked to treatment allocation and, therefore, there was the
possibility of potential bias in the ascertainment of non-disabling strokes. We therefore planned a substudy of
ICSS at centres with sufficient neuroimaging facilities and capacity in which we would use multimodal MRI as
an additional outcome measure of procedural cerebral ischaemia that could be analysed without knowledge
of treatment allocation. We aimed to compare the risk of procedural ischaemia and persistent infarction on
MRI between patients randomly allocated to receive stenting or endarterectomy. Moreover, diffusion
weighted imaging (DWI), a modern MRI technique, may show ischaemic lesions after carotid interventions
even in patients who do not experience symptoms.14 In previous studies, new ischaemic lesions on DWI
were detected more frequently after stenting than after endarterectomy.15–21 DWI lesions were also more
frequent after unprotected stenting than after protected stenting.22,23 However, selection bias and the use of
historical controls might account for the observed differences in these non-randomised comparisons. In
addition, it was not clear how ischaemic lesions on DWI relate to the risk of clinically apparent
cerebrovascular events (stroke or TIA) associated with the intervention. Larger studies with randomised
treatment allocation were needed to gain further insight into the significance of asymptomatic DWI lesions
and their potential role as surrogate markers of treatment risk.
Cerebral protection devices are used in stenting with the aim of reducing the risk of plaque embolisation
during the procedure. Recently completed randomised trials comparing the safety of stenting and
endarterectomy yielded conflicting results.24,25 Concern that stenting without cerebral protection might be
associated with an increased risk of stroke led to the abandonment of unprotected procedures in one
trial,25 but in another trial, there was no difference in the risk of stenting with and without protection.24
Although clear evidence that cerebral protection enhances treatment safety is lacking,26 protection devices
were widely used, significantly contributing to the cost of carotid stenting. We therefore planned to carry
out an exploratory analysis of the MRI data to investigate the effect of cerebral protection devices on the
risk of ischaemia associated with stenting.
METHODS
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Objectives
The primary objective of this substudy was to compare the risk of ischaemic brain injury assessed on
MRI in patients with symptomatic carotid artery stenosis undergoing stenting in comparison to those
undergoing endarterectomy.
Secondary objectives were: to assess the effect of protection devices on the risk of ischaemic brain injury
associated with stenting; to compare the risk of haemorrhagic brain injury assessed on MRI in stenting
compared with endarterectomy; and to gain further insight into the usefulness of ischaemic and
haemorrhagic brain lesions on MRI as surrogate markers of the risk of carotid interventions.
The ICSS–MRI substudy was designed to allow a randomised comparison of the procedural risk of
symptomatic and asymptomatic ischaemic and haemorrhagic brain injury visible on MRI between stenting
and endarterectomy. The use of cerebral protection devices in patients undergoing stenting was not
subject to randomisation in ICSS. However, the participating centres systematically used either protected or
unprotected stenting. The risk of brain injury associated with either stenting technique could, therefore,
be compared with a randomised control group of patients undergoing endarterectomy.
Outcome measures and analyses were defined as follows:
Primary outcome measure: rate of symptomatic and asymptomatic ischaemic brain injury detectable on
MRI after endarterectomy and stenting.
Secondary analyses:
l interaction between the use of protection devices and ischaemic brain injury in patients
undergoing stenting
l rate of symptomatic and asymptomatic haemorrhagic brain injury detectable on MRI after
endarterectomy and stenting
l relation of brain injury on MRI to risk of stroke during procedure and follow-up.
Inclusion criteria
Patients were eligible to participate in the ICSS–MRI substudy if they were enrolled in the ICSS trial and
separately provided written informed consent to undergo three MRI exams.
Exclusion criteria
Patients with contraindications to MRI (e.g. pacemakers, metallic implants and claustrophobia) were
excluded from the ICSS–MRI substudy.
Magnetic resonance imaging protocol
Patients enrolled in the ICSS–MRI substudy had three MRI investigations, at 1–3 days before, 1–3 days
after and 30± 3 days after the intervention. The following sequences were performed in all
three investigations:
l DWI to detect acute ischaemic brain injury associated with the procedure
l gradient echo T2 star-weighted sequences to detect haemorrhagic brain injury associated with
the procedure
l T1-weighted, T2-weighted and fluid-attenuated inversion recovery sequences were used to assess
whether or not acute brain lesions detected on DWI after the procedure led to permanent scarring
at 1 month.
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Data acquisition
Baseline data (such as age, sex, medical risk factors, degree of carotid stenosis, etc.) were collected
as part of ICSS. Two researchers, one a neurologist and one a neuroradiologist, with several years of
experience in assessing brain scans in patients with cerebrovascular disease independently scored the
presence, size and location (vascular territory) of ischaemic and haemorrhagic lesions on the MRI scans.
A third experienced researcher reviewed the scans in case of disagreement. The scans were reported
and scored blind to patient identifiers, treatment, date and time of the scans. Patients were clinically
examined by a neurologist at the time of MRI examination and followed up after treatment as part of
ICSS to determine outcome events, including TIA, stroke, MI and death.
Statistical analysis
The rates of ischaemic and haemorrhagic brain lesions were compared between patients undergoing
endarterectomy and stenting using chi-squared tests2 and Fisher’s exact tests. Significance was declared
at p< 0.05. Exploratory analyses were performed to test the interaction between the use of cerebral
protection devices and the rate of DWI lesions after stenting.
Sample size calculation
Power calculations for this substudy were based on the primary outcome measure. The two largest
series reported new ischaemic lesions on DWI after CEA in 17% and 34% of patients, respectively.27,28
If a rate of new DWI lesions after endarterectomy of 25% is assumed, a total sample size of
200 patients would have a 90% power to detect a twofold increase in the DWI lesion rate associated
with carotid stenting.
Effect of white-matter lesions on the risks of periprocedural
stroke after carotid artery stenting versus endarterectomy
Leukoaraiosis was associated with a higher perioperative risk of stroke or death in patients assigned to
CEA in the NASCET.29 Patients with widespread white-matter changes allocated to the best medical
management group also had an increased risk of stroke or death. To the best of our knowledge, the
effect of white-matter lesions on the procedural risk of stroke and death in carotid stenting has hitherto
not been investigated. We therefore investigated the effect of leukoaraiosis on the risk of procedural
complications in a large group of patients with recently symptomatic carotid disease randomised in ICSS
in a pre-specified analysis.30 Brain imaging by CT or MRI was needed before revascularisation.
Methods
In this study of white-matter lesions, we included all patients enrolled in ICSS in whom copies of the
baseline CT or MRI done before carotid stenting or endarterectomy were available. Patients were
excluded if no baseline brain imaging was available or if the quality of the images was poor. Copies of
baseline brain imaging were analysed by two investigators, one a neurology research fellow and
one a neuroradiologist, who were both trained in the analysis of white-matter lesions and masked
to treatment and clinical outcome, for the severity of white-matter lesions using the age-related
white-matter changes (ARWMC) score. Differences were resolved by consensus. Patients were divided
into two groups using the median ARWMC score. We analysed the risk of stroke within 30 days of
revascularisation using a per-protocol analysis. A total of 1036 patients (536 randomly allocated to CAS,
500 to CEA) had baseline imaging available. The median ARWMC score was 7, and patients were
dichotomised into those with a score of 7 or more and those with a score of < 7.
METHODS
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Cost–utility analysis of stenting versus endarterectomy for
treatment of symptomatic carotid stenosis
A cost–utility analysis with full incremental analysis was undertaken to compare the costs and outcomes
associated with stenting and endarterectomy.
Methods
Outcome measure
The outcome measure was quality-adjusted life-years (QALYs), which combine length of life and quality of
life; this is consistent with National Institute for Health and Care Excellence (NICE) recommendations.
Cost-effectiveness was expressed as incremental net monetary benefits (NMBs). The analysis took a
UK NHS and personal social services (PSS) perspective.31 Costs are calculated in 2013–14 Great British
pounds. The time horizon was 5 years, which was long enough to reflect all important differences in
costs or outcomes between the two treatments. An annual discount rate of 3.5% was applied to costs
and outcomes.31
Resource use and costs
For every patient we calculated the cost of the index procedure and the cost of follow-up using resource-use
data collected prospectively in the trial. The former included surgeon and radiologist time; operating theatre
time, including nursing staff, drugs, consumables and overheads; anaesthesia; materials and devices including
stents, shunts, patches, cerebral protection devices, catheters, wires and sheaths; and length of hospital stay
in the intensive care unit (ICU) and inpatient ward. The latter included additional carotid artery procedures;
complications within 30 days of index procedure (fatal and non-fatal MI, severe haematoma and disabling
cranial nerve palsy); imaging tests; drug treatment; and non-disabling, disabling and fatal strokes.
Unit costs were obtained from published and local sources,32–35 inflated where appropriate32 and multiplied by
resource use. Unit costs of surgeon, radiologist and operating theatre times were hourly costs applied to
procedure durations collected during the trial. The choice of stents was at the discretion of the interventionist.
In the base-case analysis each stent was assigned an acquisition cost of £840 based on the cost of the most
commonly used stent, the Carotid WALLSTENT® (Boston Scientific, Marlborough, MA, USA) at the lead centre;
this was varied in sensitivity analysis. Unit costs of hospital stays were daily costs applied to length-of-stay
data collected in the trial. Length of stay on the ICU was not collected for individual patients, but mean values
were collected by centre. From these data we assumed that where patients were admitted to the ICU
post-operatively it was for 1 day. Unit costs of additional carotid artery procedures were assumed to be equal
to the mean cost of the index procedures. Unit costs of drug treatment were monthly costs applied to
treatment durations collected in the trial. Stroke events were recorded in the trial, but the costs of managing
them were not. These were obtained from supplementary analyses of data from a contemporaneous UK
population-based study of all strokes, the Oxford Vascular (OXVASC) study,36,37 which were used to predict
care home and hospital care costs for each stroke patient as a function of their sex, age, disability before
stroke, previous history of cardiovascular disease, initial stroke severity (non-disabling, disabling, fatal) and
number of recurrent strokes (see Appendix 9).
Utilities and quality-adjusted life-years
Generic health status was described at baseline (randomisation), at 3 and 6 months, and at 1, 2, 3, 4 and
5 years post-randomisation using the EQ-5D-3L descriptive system (see www.euroqol.com), containing five
dimensions (mobility, self-care, usual activities, pain and discomfort, anxiety and depression) with three
levels in each dimension. Each EQ-5D-3L health state can be converted into a single summary index
(utility value) by applying a formula that attaches weights to each of the levels in each dimension based
on valuations by general population samples. Given the perspective of our analysis, we used a value set for
the UK population to calculate utility values at each time point for every participant.38 Utility values of
1 represent full health, values of 0 are equivalent to death, negative values represent states worse than
death. Patients who died were assigned a utility value of 0 at their date of death. A utility profile was
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constructed for every patient assuming a straight line relation between their utility values at each
measurement point. QALYs for every patient from baseline to 5 years were calculated as the area under
the utility profile.
Dealing with missing data
Multiple imputation was used to impute missing data for the following variables: cost of surgeon and
radiologist time; cost of operating theatre time; cost of anaesthesia; cost of stents; cost of patches; cost of
cerebral protection devices; cost of other materials used in stenting; cost of length of hospital stay; cost
of non-fatal MI; cost of imaging tests; costs of drug treatment; cost of strokes; total cost; utility values at
baseline, 3 months and 6 months post-randomisation, and 1, 2, 3, 4 and 5 years post-randomisation;
and total QALYs. The cost variables were unit costs multiplied by resource use. Age, sex, study centre and
treatment allocation were included in the imputation models as additional explanatory variables. We
used multivariate normal regression to impute missing values and generated 20 imputed data sets.
We repeated the multiple imputation several times using different random number seeds to investigate
if the conclusions of the analysis changed.
Statistical methods
Mean costs, outcomes and NMBs were compared between all patients randomly assigned to stenting and
to endarterectomy, irrespective of which treatment was administered and whether or not they received
additional carotid artery procedures of either type. We calculated differences in mean costs and QALYs and
incremental NMBs between groups. NMBs for stenting and endarterectomy were calculated as the mean
QALYs per patient multiplied by the maximum willingness to pay for a QALY minus the mean cost per
patient. Incremental NMBs were calculated as the difference in mean QALYs per patient with stenting
versus endarterectomy multiplied by the maximum willingness to pay for a QALY minus the difference
in mean cost per patient. We used the cost-effectiveness threshold range recommended by NICE of
£20,000 to £30,00031 as the lower and upper limits of the maximum willingness to pay for a QALY. If the
incremental NMB is positive (negative) then stenting (endarterectomy) was preferred on cost-effectiveness
grounds. The QALYs gained were adjusted for age, sex, study centre and baseline utility values using
regression analysis; the incremental costs were adjusted for age, sex and study centre. For each of
the 20 imputed data sets we ran 1000 bootstrap replications and combined the results using equations
described by Briggs et al.39 to calculate standard errors around mean values accounting for uncertainty in
the imputed values, the skewed nature of the cost data and utility values, and sampling variation. Standard
errors were used to calculate 95% CIs around point estimates.
Sensitivity and subgroup analyses
A cost-effectiveness acceptability curve40 showing the probability that stenting was cost-effective compared
with endarterectomy at a range of values for the maximum willingness to pay for a QALY was generated
based on the proportion of the bootstrap replications across all 20 imputed data sets with positive
incremental NMBs.41 The probability that stenting was cost-effective at a maximum willingness to pay
for a QALY of £20,000 and £30,000 was reported, based on the proportion of bootstrap replications
with positive incremental NMBs at these values. We undertook further sensitivity analyses to evaluate the
impact of uncertainty in the following components: no adjustment for age, sex, study centre and baseline
utility values; complete-case analysis without imputing missing values; univariate analyses of high- and
low-cost values (unit costs multiplied by resource use) for anaesthesia, operating theatre time, surgeon
and radiologist time, shunts, patches, stents, cerebral protection devices, other materials used in stenting,
length of hospital stay, additional carotid artery procedures, imaging, severe haematoma, disabling cranial
nerve palsy, fatal and non-fatal MI, drug treatment, treating strokes (values per patient were recalculated
to be 50% higher and 50% lower than the base case); and discount rate (1.5%, 5%). No significant
interactions were found in any subgroup analyses of the primary outcomes in ICSS. In post-hoc subgroup
analyses we calculated cost-effectiveness results separately by sex and age (≥ 70 years, < 70 years). We
completed a Consolidated Health Economic Evaluation Reporting Standards statement to ensure that the
cost–utility analysis was reported appropriately (see Appendix 9).
METHODS
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Chapter 3 Results
The short-term and long-term outcomes of ICSS have been reported in the literature.42,43
Recruitment
Figure 1 shows the CONSORT diagram of the flow of patients through the trial. Between May 2001 and
October 2008, 1713 patients from 50 centres in the UK, mainland Europe, Australia, New Zealand
and Canada were enrolled and randomised. The trial centres, together with the members of the trial
committees, location of recruiting centres, number of patients recruited at each centre and the names of
the investigators at each centre are detailed in Appendix 10. Three patients (two in the stenting group and
one in the endarterectomy group) withdrew consent immediately after randomisation and were excluded
from the intention-to-treat (ITT) analysis. In total, 1511 patients were enrolled at experienced centres
and 202 at supervised probationary centres: 751 (88%) of 853 patients assigned to carotid stenting
and 760 (89%) of 857 patients assigned to endarterectomy were randomised at centres classified as
experienced. Most patients had their allocated treatment initiated (stenting group, n= 828; endarterectomy
group, n= 821). Nine patients allocated to stenting crossed over to surgery without an attempt at the
procedure and a further 16 had no attempted ipsilateral endarterectomy or stenting procedure (Figure 1).
Fifteen patients allocated to endarterectomy crossed over to stenting without an attempt at endarterectomy
and 21 had no attempted ipsilateral procedure.
Monitoring of adverse events led to concern about the stenting results of two investigators at supervised
centres. These investigators were stopped from treating further patients within the trial and their centres
were suspended from randomisation. All the patients allocated to stenting (n= 11, five with disabling
stroke or death) or endarterectomy during the same time period (n= 9, one with fatal stroke) at these
centres were included in the analyses. One of the two centres subsequently restarted randomisation with
a different investigator performing stenting.
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Patients randomised
(n = 1713)
Assigned to stenting
(n = 855)
Withdrew all consent immediately
after randomisation
(n = 2)
Analysed by intention to treat
from randomisation until
end of follow-up
(n = 853)
Stenting initiated
(n = 828)
Stenting aborted
(n = 64)
No ultrasound
post procedure
(n = 27)
Analysed for
restenosis from date
of procedure until
last ultrasound
(n = 737)
Analysed per protocol
from 31 days post
procedure to end
 of follow-up
(n = 752)
Follow-up < 30 days (n = 12)
• Fatal events, n = 10
• Had no further follow-up,
   n = 2
Crossed over to endarterectomy
(n = 9)
• Anatomy unsuitable, n = 2
• Medical contraindications, n = 3
• Refused treatment, n = 1
• Other reasons, n = 3
Underwent no procedure (n = 16)
• Disabling stroke before
   intended procedure, n = 1
• Artery occluded, n = 5
• Artery less than 50% stenosed,
   n = 3
• Anatomy unsuitable, n = 1
• Other medical contraindications,
   n = 3
• Other reasons, n = 3
Assigned to endarterectomy
(n = 858)
Withdrew all consent immediately
after randomisation
(n = 1)
Analysed by intention to treat
from randomisation until
end of follow-up
(n = 857)
Endarterectomy initiated
(n = 821)
Endarterectomy aborted
(n = 2)
No ultrasound
post procedure
(n = 26)
Analysed for
restenosis from date
of procedure until
last ultrasound
(n = 793)
Analysed per protocol
from 31 days post
procedure to end
 of follow-up
(n = 811)
Follow-up < 30 days (n = 8)
• Fatal events, n = 4
• Had no further follow-up,
   n = 4
Crossed over to stenting (n = 15)
• Anatomy unsuitable, n = 1
• Medical contraindications, n = 6
• Refused treatment, n = 4
• Other reasons, n = 4
Underwent no procedure (n = 21)
• Died before intended procedure,
   n = 2
• Disabling stroke before
   intended procedure, n = 3
• Artery occluded, n = 9
• Artery less than 50% stenosed,
   n = 1
• Medical contraindications, n = 3
• Refused treatment, n = 1
• Other reasons, n = 2
FIGURE 1 Consolidated Standards of Reporting Trials diagram for ICSS.
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Baseline characteristics
Table 1 shows baseline characteristics of study participants.
Patient baseline characteristics (Table 1) and drug treatment during the trial (Table 2) were similar between
the two treatment groups. At 1 year after randomisation, 97% of patients in both the stenting group
and the endarterectomy group took any antiplatelet or anticoagulant; at 5 years, the percentages were
94% and 95% (Table 2). There were slightly more patients taking antihypertensive medications in the
endarterectomy group at 1 year (71% vs. 75%; p= 0.088), but at 5 years the difference had reversed
(83% vs. 76%; p= 0.017). However, this did not lead to any significant difference in systolic blood
pressure or diastolic blood pressure (DBP) between groups at either time point. The majority of patients
were treated with lipid-lowering medications with no significant difference between the groups (82% of
patients in the CAS group vs. 84% in the CEA group at 1 year, and 87% of patients in the CAS group vs.
86% in the CEA group at 5 years).
TABLE 1 Baseline patient characteristics at randomisation by allocated treatment
Baseline patient characteristic Stenting (n= 853) Endarterectomy (n= 857)
Age (years), mean (SD) 70 (9) 70 (9)
Male sex, n (%) 601 (70) 606 (71)
Vascular risk factors
Treated hypertension, n (%) 587 (69) 596 (70)
Systolic blood pressure (mmHg), mean (SD) 147 (24) 146 (24)
Diastolic blood pressure (mmHg), mean (SD) 79 (12) 78 (13)
Cardiac failure, n (%) 23 (3) 47 (5)
Angina in last 6 months, n (%) 83 (10) 77 (9)
Previous MI, n (%) 151 (18) 156 (18)
Previous CABG, n (%) 109 (13) 116 (14)
Atrial fibrillation, n (%) 57 (7) 59 (7)
Other cardiac embolic source, n (%) 19 (2) 16 (2)
Diabetes mellitus, non-insulin dependent, n (%) 134 (16) 147 (17)
Diabetes mellitus, insulin dependent, n (%) 50 (6) 41 (5)
Peripheral artery disease, n (%) 139 (16) 136 (16)
Current smoker, n (%) 205 (24) 198 (23)
Ex-smoker, n (%) 408 (48) 424 (49)
Treated hyperlipidaemia, n (%) 522 (61) 563 (66)
Total serum cholesterol (mmol/l), mean (SD) 4.8 (1.3) 4.9 (1.3)
Degree of symptomatic carotid stenosis, n (%)a
50–69% 92 (11) 76 (9)
70–99% 761 (89) 781 (91)
Degree of contralateral carotid stenosis, n (%)a
< 50% 565 (66) 561 (65)
50–69% 128 (15) 142 (17)
70–99% 105 (12) 110 (13)
Occluded 49 (6) 37 (4)
Unknown 6 (1) 7 (1)
continued
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TABLE 1 Baseline patient characteristics at randomisation by allocated treatment (continued )
Baseline patient characteristic Stenting (n= 853) Endarterectomy (n= 857)
Most recent ipsilateral event, n (%)b
Ischaemic hemispheric stroke 393 (46) 376 (44)
TIA 273 (32) 303 (35)
Retinal infarction 26 (3) 23 (3)
Amaurosis fugax 148 (17) 142 (17)
Unknown 13 (2) 13 (2)
Event < 6 months prior to randomisation 826 (97) 816 (95)
Event 6–12 months prior to randomisationc 27 (3) 36 (4)
mRS at randomisation, n (%)
0–2 756 (89) 744 (87)
3–5d 81 (10) 99 (12)
CABG, coronary artery bypass graft; SD, standard deviation.
a Degree of stenosis reported by randomising centre according to the measure used in the NASCET or a
non-invasive equivalent.
b If two events were reported on the same day, the one higher up in the order above was counted.
c In three patients the event was more than 12 months before randomisation and in two the date was unknown.
d Some Rankin scores of ≥ 3 were caused by non-stroke disability.
TABLE 2 Drug treatment and blood pressure readings during follow-up (ITT population)
Drug treatment and blood pressure
1 year 5 years
Stenting Endarterectomy Stenting Endarterectomy
Drug treatment (number of patients with data) 714 751 343 329
Any antiplatelet, n (%) 668 (94) 688 (92) 303 (88) 284 (86)
Aspirin alone, n (%) 401 (56) 413 (55) 197 (57) 169 (51)
Clopidogrel alone, n (%) 79 (11) 79 (11) 40 (12) 46 (14)
Dipyridamole+ aspirin or clopidogrel, n (%) 130 (18) 154 (21) 48 (14) 48 (15)
Aspirin+ clopidogrel, n (%) 55 (8) 34 (5) 14 (4) 17 (5)
Anticoagulation: vitamin K antagonists, n (%) 36 (5)a 57 (8)a 23 (7) 33 (10)
Other anticoagulation or antiplatelet, n (%) 3 (0) 10 (1) 5 (1) 4 (1)
Any anticoagulation or antiplatelet, n (%) 696 (97) 731 (97) 322 (94) 313 (95)
Antihypertensive, n (%) 510 (71) 566 (75) 286 (83)a 250 (76)a
Lipid lowering, n (%) 584 (82) 629 (84) 299 (87) 282 (86)
Blood pressure (n patients with data) 664b 685b 313b 302b
Systolic blood pressure (mmHg), mean (SD) 147 (22)a 144 (22)a 142 (22) 143 (23)
Diastolic blood pressure (mmHg), mean (SD) 79 (12)a 78 (11)a 77 (12) 76 (12)
SD, standard deviation.
a Statistical comparison between treatment groups (chi-squared test for specified drug treatments and t-test for blood
pressures): p < 0.05. ‘Anticoagulation’ (1 year; p= 0.046); ‘antihypertensive’ (5 year; p= 0.017); ‘systolic blood pressure’
(1 year; p= 0.011); ‘diastolic blood pressure’ (1 year; p= 0.035).
b For diastolic blood pressure, numbers of patients with data are 663 and 684 (1 year), and 312 and 301 (5 year).
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Success of procedures and cross-overs
Figure 2 shows the delay from randomisation to first initiated ipsilateral treatment in the per-protocol
analysis within the first 120 days after randomisation.
Median delay from randomisation to treatment was shorter in the stenting group than in the
endarterectomy group, as was the delay from most recent ipsilateral event to treatment (Table 3).
Of the 828 patients in whom stenting was initiated as allocated, 64 (8%) had their procedure aborted before
the insertion of a stent (38 procedures were aborted because of difficulty gaining access to the stenosis;
15 were aborted because of the finding of an occluded artery, one patient had a fatal stroke, one patient
had a fatal MI before completion of treatment, two had other medical complications, and further
investigation in seven patients showed the artery to be < 50% stenosed). Of the 62 patients whose stenting
procedure was aborted after initiation and who did not have a fatal event, 37 went on to have an ipsilateral
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FIGURE 2 Time between randomisation and treatment. Cumulative number of patients in whom allocated
treatment was initiated per protocol plotted as a proportion (%) of the total number randomised in each
treatment group (y-axis), against the delay in days between the dates of randomisation and treatment (x-axis).
Only allocated per-protocol treatment dates were counted.
TABLE 3 Time from randomisation and from most recent ipsilateral event to allocated treatment
Stenting (n= 828) Endarterectomy (n= 821) p-valuea
Time from randomisation to treatment (days),
median (IQR)
9 (5–17) 11 (5–24) < 0.001
≤ 14 days, n (%) 578 (70) 469 (57)
> 14 days, n (%) 250 (30) 352 (43)
Time from most recent event to treatment (days),
median (IQR)
35 (15–82) 40 (18–87) 0.013
≤ 14 days, n (%) 205 (25) 151 (18)
> 14 days, n (%) 623 (75) 668 (81)
a Mann–Whitney U-test.
Three patients were randomised more than 12 months after symptoms in the endarterectomy group. The date of the most
recent event was unknown in two patients (endarterectomy group).
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endarterectomy, whereas 25 continued with best medical care only. Only two of the 821 patients whose
allocated endarterectomy was initiated had their procedure aborted (one patient had an allergic reaction
during general anaesthesia; the other became distressed and the endarterectomy had to be abandoned).
Both patients subsequently had ipsilateral stenting.
The following stents were each used in 10% or more of the 764 patients in whom stents were inserted:
Carotid WALLSTENT® (Boston Scientific), Precision (Cordis®, Freemont, CA, USA), and Protege™ (EV3®,
Dublin, Ireland). The following were each used in < 10% of patients: Acculink (Guidant™, Santa Clara,
CA, USA), XACT® (Abbott™, Santa Clara, CA, USA), S.M.A.R.T.® (Cordis®, Miami Lakes, FL, USA),
Cristallo Ideale (Invatec, Roncadelle, Brescia, Italy), Exponent (Medtronic®, Minneapolis, MN, USA), Next Stent
(Boston Scientific). Protection devices were known to have been used in 593 (72%) of 828 patients.
The following protection devices were each used in 10% or more of the patients in whom stenting was
attempted: FilterWire EZ™ (Boston Scientific), ANGIOGUARD® (Cordis), SpiderFX™ (EV3) and Emboshield®
(Abbott). A range of other protection devices were used in < 5% of patients. In 27 patients, it was not
clear whether or not a protection device was used.
Short-term outcomes
In the ITT analysis, between randomisation and 120 days, there was no significant difference in the rate
of disabling stroke or death between groups (stenting group, 4.0% vs. endarterectomy group, 3.2%;
Table 4). The risk of stroke, death or procedural MI 120 days after randomisation was significantly
higher in patients in the stenting group than in patients in the endarterectomy group (8.5% vs. 5.1%),
representing an estimated 120-day absolute risk difference of 3.3% (95% CI 0.9% to 5.7%) with a
HR in favour of surgery of 1.69 (1.16 to 2.45, log-rank p-value= 0.006) (Figure 3 and Table 4).
Most outcome events, within 120 days of randomisation in the stent and endarterectomy groups occurred
within 30 days of the first ipsilateral procedure (61 of 72 events vs. 31 of 44 events). A few events
occurred after randomisation but before the date of treatment (two patients vs. one patient) in patients
who had no attempted ipsilateral procedure (three patients vs. six patients), or more than 30 days after
treatment but within 120 days of randomisation (six patients vs. six patients). Compared with
TABLE 4 Intention-to-treat analyses: outcome measures within 120 days of randomisation
Outcome measures
CAS N= 853,
n (%)
CEA N= 857,
n (%) HR (95% CI) RD (95% CI) p-valuea
Main outcome
Stroke, death or
procedural MI
72 (8.5) 44 (5.2) 1.69 (1.16 to 2.54) 3.3 (0.9 to 5.7) 0.006
Secondary outcomes
Any stroke 65 (7.7) 35 (4.1) 1.92 (1.27 to 2.89) 3.5 (1.3 to 5.8) 0.002
Any stroke or death 72 (8.5) 40 (4.7) 1.86 (1.26 to 2.74) 3.8 (1.4 to 6.1) 0.001
Any stroke or
procedural death
68 (8.0) 36 (4.2) 1.95 (1.30 to 2.92) 3.8 (1.5 to 6.0) 0.001
Disabling stroke or
death
34 (4.0) 27 (3.2) 1.28 (0.77 to 2.11) 0.8 (–0.9 to 2.6) 0.34
All-cause death 19 (2.3) 7 (0.8) 2.76 (1.16 to 6.56) 1.4 (0.3 to 2.6) 0.017
RD, risk difference.
a Log-rank test.
Data are number of first events (Kaplan–Meier estimate at 120 days), HRs or risk differences (95% CI). Risk differences are
calculated from Kaplan–Meier estimates at 120 days.
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FIGURE 3 Kaplan–Meier estimates of cumulative incidence of main short-term outcome measures. Data are analysed
by ITT. The numbers above the end of the lines are the incidence estimates at 120 days after randomisation. (a) Stroke,
death or procedural MI (primary outcome measure); (b) any stroke; (c) stroke or death; (d) disabling stroke or death;
(e) all-cause death and (f) any stroke or procedural death. (continued )
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FIGURE 3 Kaplan–Meier estimates of cumulative incidence of main short-term outcome measures. Data are analysed
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death or procedural MI (primary outcome measure); (b) any stroke; (c) stroke or death; (d) disabling stroke or death;
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endarterectomy, allocation to stenting had a greater 120-day risk of the outcome measures of any stroke,
any stroke or death, any stroke or procedural death, and all-cause death (Table 4).
Most strokes within 120 days of randomisation were ipsilateral to the treated carotid artery and most were
ischaemic (Table 5). There were very few haemorrhagic strokes, with only two patients in whom the cause
of the stroke was uncertain.
The observed treatment effect was largely driven by the higher number of non-disabling strokes in the
stenting group, most of which had symptoms lasting for more than 7 days. There was an excess of fatal
strokes in the stenting group compared with the surgery group, but little difference in the number of
patients with disabling stroke within 120 days of randomisation.
TABLE 5 Number of outcome events recorded between randomisation and 120 days in the ITT analysis, and
between initiation of treatment and 30 days after treatment in the per-protocol analysis
Outcome events
ITT analysis: events up to 120 days
after randomisation, n (%)
Per-protocol analysis: events between
0 days and 30 days after treatment, n (%)
Stenting,
(N= 853)
Endarterectomy,
(N= 857)
Stenting,
(N= 828)
Endarterectomy,
(N= 821)
Any stroke 65 (7.6)a 35 (4.1) 58 (7.0)a 27 (3.3)
Ipsilateral stroke 58 (6.8) 30 (3.5) 52 (6.3) 25 (3.0)
Ischaemic stroke 63 (7.4) 28 (3.3) 56 (6.8) 21 (2.6)
Haemorrhagic stroke 3 (0.4) 5 (0.6) 2 (0.2) 5 (0.6)
Uncertain pathology 0 2 (0.2) 0 1 (0.1)
Non-disabling stroke 39 (4.6) 14 (1.6) 36 (4.6) 11 (1.3)
Lasting < 7 days 9 (1.1) 5 (0.6) 8 (1.0) 5 (0.6)
Lasting > 7 days 31 (3.6)b 9 (1.1)c 29 (3.5)b 6 (0.7)c
Disabling stroke 17 (2.0)d 20 (2.3) 14 (1.7) 14 (1.7)
Fatal stroke 9 (1.1) 2 (0.2) 8 (1.0) 3 (0.4)
Procedural MI 3 (0.4) 4 (0.5) 3 (0.4) 5 (0.6)
Non-fatal MI 0 4 (0.5) 0 5 (0.6)e
Fatal MI 3 (0.4) 0 3 (0.4) 0
Non-stroke, non-MI death 7 (0.8) 5 (0.6) 1 (1.0) 1 (0.1)
Cranial nerve palsy 1 (0.1)f 45 (5.5) 1 (1.0)f 45 (5.5)
Disabling cranial nerve palsy 1 (0.1)f 1 (0.1) 1 (1.0)f 1 (0.1)
Haematoma 31 (3.6) 50 (5.8) 30 (3.6) 50 (6.0)
Severe haematoma
g
9 (1.1) 28 (3.3) 8 (1.0) 28 (3.4)
a In two patients this was retinal infarction.
b One patient had a subsequent fatal MI and one patient also had a non-disabling stroke that lasted for more than 7 days.
c One patient had a subsequent disabling stroke.
d Two patients subsequently died of non-stroke, non-MI cause.
e One patient had a non-fatal MI within 30 days of their first procedure, which was performed > 120 days after
randomisation. This MI was therefore excluded from the ITT analysis (which stopped at 120 days) but was included in
the per-protocol 30-day analysis which included all first ipsilateral allocated procedures.
f The cranial nerve palsy in this patient allocated CAS, which was initiated but aborted, occurred after CEA carried out
within 30 days of the stent procedure.
g Severe haematoma was defined as one that required surgical evacuation or blood transfusion, or resulted in prolonged
hospital stay.
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The per-protocol analysis included 1649 patients (stenting group, n= 828; endarterectomy group,
n= 821). Results for 30-day procedural risk mirrored the results of the ITT analysis. Risk of stroke, death or
procedural MI was higher in the stenting group than in the endarterectomy group (30-day risk 7.4% vs.
4.0%) [risk difference (RD) 3.3%, 95% CI 1.1% to 5.6%; risk ratio (RR) 1.83, 95% CI 1.21 to 2.77;
χ2 p= 0.003] (Table 6). Risk of any stroke or death up to 30 days after treatment remained significantly
higher in patients in whom stenting was initiated than in patients with surgery initiated, but there was no
significant difference in the risk of disabling stroke or death between treatment groups. There were more
fatal strokes in the stenting group than in the endarterectomy group (eight vs. three), but difference in the
risk of death alone was no longer significant (see Table 5). Forty-three (74%) of 58 strokes in the stenting
group and 12 (44%) of 27 strokes in the endarterectomy group occurred on the day of the procedure.
There was no difference in the numbers of strokes occurring between day 2 and day 30 between the
two treatments (15 vs. 15).
Few procedural MIs were recorded (three in the stenting group, all of which were fatal, compared with
five in the endarterectomy group). Cranial nerve palsies were almost completely avoided by stenting
(RR 0.02, 95% CI 0.00 to 0.16; p< 0.0001) (see Table 5). The one cranial nerve palsy recorded in the
stenting group occurred as a complication of an endarterectomy performed within 30 days of stenting.
This patient and one additional patient in the endarterectomy group required percutaneous endoscopic
gastrostomy feeding as a result of the cranial nerve palsies, which was classified as disabling. There
were also fewer haematomas of any severity in the stenting group than in the endarterectomy group
(RR 0.59, 95% CI 0.38 to 0.93; p= 0.0197), and fewer severe haematomas requiring surgical intervention,
blood transfusion or extended hospital stay (RR 0.28, 95% CI 0.13 to 0.62; p= 0.0007) (see Table 5).
A post-hoc sensitivity analysis was undertaken to examine if the results of the per-protocol analysis were
affected by inclusion of patients in whom the allocated procedure was initiated but not completed.
Exclusion of the 64 patients allocated to stenting and two patients allocated to endarterectomy in whom
the procedures were aborted after initiation (i.e. including only patients in whom the allocated procedure
was completed as planned) made little difference to the results (30-day risk of stroke, death or procedural
MI of 7.6% in the stenting group vs. 4.0% in the endarterectomy group) (RD 3.6%, 95% CI 1.3% to
5.9%; RR 1.88, 95% CI 1.24 to 2.86; p= 0.002).
TABLE 6 Per-protocol analysis of procedural risk: outcome measures between initiation of treatment and 30 days
after treatment
Outcome measures
CAS N= 828,
n (%)
CEA N= 821,
n (%) RR (95% CI) RD (95% CI) p-valuea
Main outcome
Stroke, death or MI 61 (7.4) 33 (4.0) 1.83 (1.21 to 2.77) 3.3 (1.1 to 5.6) 0.003
Secondary outcomes
Any stroke 58 (7.0) 27 (3.3) 2.13 (1.36 to 3.33) 3.7 (1.6 to 5.8) 0.001
Any stroke or death 61 (7.4) 28 (3.4) 2.16 (1.40 to 3.34) 4.0 (1.8 to 6.1) 0.0004
Disabling stroke or death 26 (3.1) 18 (2.2) 1.43 (0.79 to 2.59) 0.9 (–0.6 to 2.5) 0.23
Procedural death 11b (1.3) 4 (0.5) 2.73 (0.87 to 8.53) 0.8 (–0.1 to 1.8) 0.072
a Chi-squared test.
b One patient had a fatal stroke but died more than 30 days after the procedure. The event is therefore counted in the
fatal stroke outcome but not the procedural death outcome.
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We undertook exploratory analyses of the composite outcome of stroke, death or procedural MI for
pre-defined subgroups (Figure 4). These analyses suggested that carotid stenting might have a similar risk
to endarterectomy in women, but that the intervention was more hazardous than endarterectomy in men.
The difference was mainly caused by a higher risk of stroke, death or procedural MI in women assigned to
endarterectomy than in men (7.6% vs. 4.2%). However, the difference between the HRs comparing the
risk of stenting with endarterectomy in men and women only reached borderline significance (interaction
p= 0.071). Stenting was more hazardous, and endarterectomy less hazardous, in patients not taking
medication for hypertension at baseline than in patients taking medication for hypertension (see Figure 4).
There was also a suggestion that patients who presented with multiple ipsilateral symptoms had a similar
risk of stroke death, or procedural MI with stenting and endarterectomy. However, when compared with
patients with only one event before randomisation, the difference in the HRs only reached borderline
significance (interaction p= 0.055). There was no evidence that the relative increase in the hazard of an
event in the stenting group compared with the endarterectomy group differed significantly across any
other subgroups.
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Duration of follow-up in the International Carotid Stenting Study
Figure 5 shows the number of patients remaining in follow-up in ICSS plotted against time from
randomisation. Patients were followed up for a maximum of 10 years after randomisation with a median
of 4.2 years and an interquartile range of 3.0–5.2 years. This amounted to 7355 patient-years of follow-up,
without any difference between the two arms.
Long-term primary and secondary outcomes
In the ITT analysis, the primary outcome event, fatal or disabling stroke between randomisation and the
end of follow-up, occurred in 52 patients in the stenting group, corresponding to a cumulative 5-year risk
of 6.4%, and in 49 patients in the endarterectomy group (5-year risk n, 6.5%), without any evidence for a
difference in time to first occurrence of an event (HR 1.06, 95% CI 0.72 to 1.57; p= 0.76) (Table 7
and Figure 6).
The following secondary outcome events occurred significantly more often in the stenting group in the
ITT analysis between randomisation and the end of follow-up: any stroke (5-year risks 15.2% vs. 9.4%)
(HR 1.71, 95% CI 1.28 to 2.30; p= 0.0003); any stroke or death (27.5% vs. 22.6%) (HR 1.34, 95% CI
1.11 to 1.63; p= 0.003); the combination of any procedural stroke, procedural death or ipsilateral
stroke during follow-up (11.8% vs. 7.2%) (HR 1.72, 95% CI 1.24 to 2.39; p= 0.001). There was no
difference in all-cause mortality between treatment groups (17.4% vs. 17.2%) (HR 1.17, 95% CI 0.92
to 1.48; p= 0.19).
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FIGURE 5 Patients remaining in each arm of the study (per protocol) are plotted against year of follow-up. In total,
there are 7354.45 patient-years of follow-up until time of last follow-up or death. CAS (n=853): median
follow-up=4.2 years, interquartile range (IQR) 3.0–5.4 years (maximum=10.0 years, 153 deaths); CEA (n=857):
median follow-up=4.2 years, IQR 3.0–5.2 years (maximum=9.6 years, 129 deaths).
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FIGURE 6 Kaplan–Meier estimates of cumulative incidence of major long-term outcome measures. (a) Fatal or
disabling stroke; (b) any stroke; (c) procedural stroke or death, or ipsilateral stroke during follow up; (d) any stroke
> 30 days after treatment; (e) ipsilateral stroke > 30 days after treatment; (f) contralateral carotid or vertebrobasilar
stroke > 30 days after treatment; (g) ipsilateral carotid stenosis (≥ 70%) or occlusion during follow-up; and
(h) all-cause death. Data were analysed by ITT from randomisation except for parts (d) to (f), which are analysed in the
per-protocol population from 30 days post procedure, and part (g) which is analysed in the per-protocol population
from treatment. The numbers on the lines are the estimated 1-year and 5-year cumulative incidences. The graphs
have only been plotted to 7 years’ follow-up because the numbers with longer follow-up were < 100. However, the
HRs were calculated using all relevant outcome events until the end of follow-up (maximum 10 years). (continued )
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FIGURE 6 Kaplan–Meier estimates of cumulative incidence of major long-term outcome measures. (a) Fatal or
disabling stroke; (b) any stroke; (c) procedural stroke or death, or ipsilateral stroke during follow up; (d) any stroke
> 30 days after treatment; (e) ipsilateral stroke > 30 days after treatment; (f) contralateral carotid or vertebrobasilar
stroke > 30 days after treatment; (g) ipsilateral carotid stenosis (≥ 70%) or occlusion during follow-up; and
(h) all-cause death. Data were analysed by ITT from randomisation except for parts (d) to (f), which are analysed in the
per-protocol population from 30 days post procedure, and part (g) which is analysed in the per-protocol population
from treatment. The numbers on the lines are the estimated 1-year and 5-year cumulative incidences. The graphs
have only been plotted to 7 years’ follow-up because the numbers with longer follow-up were < 100. However, the
HRs were calculated using all relevant outcome events until the end of follow-up (maximum 10 years). (continued )
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FIGURE 6 Kaplan–Meier estimates of cumulative incidence of major long-term outcome measures. (a) Fatal or
disabling stroke; (b) any stroke; (c) procedural stroke or death, or ipsilateral stroke during follow up; (d) any stroke
> 30 days after treatment; (e) ipsilateral stroke > 30 days after treatment; (f) contralateral carotid or vertebrobasilar
stroke > 30 days after treatment; (g) ipsilateral carotid stenosis (≥ 70%) or occlusion during follow-up; and
(h) all-cause death. Data were analysed by ITT from randomisation except for parts (d) to (f), which are analysed in the
per-protocol population from 30 days post procedure, and part (g) which is analysed in the per-protocol population
from treatment. The numbers on the lines are the estimated 1-year and 5-year cumulative incidences. The graphs
have only been plotted to 7 years’ follow-up because the numbers with longer follow-up were < 100. However, the
HRs were calculated using all relevant outcome events until the end of follow-up (maximum 10 years).
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A total of 752 patients in the stenting group (88.2% of the ITT population) and 811 patients in the
endarterectomy group (94.6%) were included in the per-protocol analysis of clinical outcome events. In the
per-protocol analysis of events occurring more than 30 days after completed treatment up to the end of
follow-up, there was no significant difference in the long-term risks of fatal and disabling stroke after stenting
compared with endarterectomy (5-year risk 3.4% vs. 4.3%) (HR 0.93, 95% CI 0.53 to 1.60; p= 0.78) (Table 8).
There was also no significant difference in the rates of ipsilateral stroke in the territory of the treated carotid
artery (4.7% vs. 3.4%) (HR 1.29, 95% CI 0.74 to 2.24; p= 0.36). However, stroke of any severity occurred
more often after stenting (8.9% vs. 5.8%) (HR 1.53, 95% CI 1.02 to 2.31; p= 0.039) (Figure 6 and Table 8).
This difference was largely attributable to stroke occurring in the territory of the contralateral carotid artery or
the vertebrobasilar circulation among patients treated with stents (5-year risks 4.6% vs. 2.5%) (HR 1.92,
95% CI 1.04 to 3.53; p= 0.033) and the majority were non-disabling.
A total of 737 (98.0%) patients in the stenting group and 793 (97.8%) in the endarterectomy group were
followed up with carotid ultrasound for a median of 4.0 years (interquartile range, 2.3–5.0 years) after
treatment. There was no significant difference in long-term rates of severe carotid restenosis (≥ 70%) or
occlusion, which occurred in 72 patients in the stenting group (5-year risk 10.8%) and in 62 patients in
the endarterectomy group (5-year risk 8.6%) (HR 1.25, 95% CI 0.89 to 1.75; p= 0.20; see Table 8
and Figure 6).
Exploratory subgroup analyses showed no significant modification of the HR of the primary outcome event
(Figure 7), nor of the combined outcome of procedural death or stroke, or non-procedural ipsilateral stroke
by any of the evaluated variables (Figure 8).
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Long-term functional outcome
There was no difference in distribution of functional disability as measured by the mRS scores at the end of
follow-up, nor was there any significant difference 1 or 5 years after randomisation (Figure 9).
Findings of the magnetic resonance imaging substudy
The MRI substudy has been previously published in detail.44 A total of 231 patients (124 in the stenting
group and 107 in the endarterectomy group) had MRI before and after treatment. Sixty-two (50%) of
124 patients in the stenting group and 18 (17%) of 107 patients in the endarterectomy group had
at least one new DWI lesion detected on post-treatment scans done a median of 1 day after treatment
[adjusted odds ratio (OR) 5.21, 95% CI 2.78 to 9.79; p< 0.0001]. At 1 month, there were changes
on fluid-attenuated inversion recovery sequences in 28 (33%) of 86 patients in the stenting group and
1-year follow-up(a)
5-year follow-up
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(n = 488)
CEA
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FIGURE 9 The distribution of scores on the mRS: (a) after 1-year and 5-year follow-up in patients allocated CAS or
CEA using the Rankin scores in patients still surviving and in follow-up or who had died before at the indicated
time points [permutation test comparing Rankin scores between the two groups at 1 year (unadjusted p= 0.70,
adjusted for baseline mRS p= 0.11), at 5 years (unadjusted p= 0.54, adjusted for baseline mRS p= 0.98)13]; (b) at the
last follow-up recorded for the patient, regardless of duration (unadjusted, p= 0.49; adjusted for baseline mRS
score, p= 0.24).
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six (8%) of 75 in the endarterectomy group (adjusted OR 5.93, 95% CI 2.25 to 15.62; p= 0.0003).
In patients treated at a centre with a policy of using cerebral protection devices, 37 (73%) of 51 in the
stenting group and eight (17%) of 46 in the endarterectomy group had at least one new DWI lesion on
post-treatment scans (adjusted OR 12.20, 95% CI 4.53 to 32.84), whereas in those treated at a centre
with a policy of unprotected stenting, 25 of 73 patients (34%) in the stenting group and 10 of 61 (16%)
in the endarterectomy group had new lesions on DWI (adjusted OR 2.70, 95% CI 1.16 to 6.24;
interaction p= 0.019).
Studies on the predictors of risk of individual procedures
Findings of study on the effect of white-matter lesions on the risk of
periprocedural stroke
This analysis has been published in detail elsewhere.30 Patients were divided into two groups using the
median ARWMC. We analysed the risk of stroke within 30 days of revascularisation using a per-protocol
analysis. A total of 1036 patients (536 randomly allocated to CAS, 500 to CEA) had baseline imaging
available. Median ARWMC score was 7, and patients were dichotomised into those with a score of 7
or more and those with a score of < 7. In patients treated with CAS, those with an ARWMC score of 7 or
more had an increased risk of stroke compared with those with a score of < 7 (HR for any stroke 2.76,
95% CI 1.17 to 6.51; p= 0.021; HR for non-disabling stroke 3.00, 95% CI 1.10 to 8.36; p= 0.031).
However, we did not see a similar association in patients treated with CEA (HR for any stroke 1.18,
95% CI 0.40 to 3.55; p= 0.76; HR for disabling or fatal stroke 1.41, 95% CI 0.38 to 5.26; p= 0.607).
Carotid artery stenting was associated with a higher risk of stroke compared with CEA in patients with an
ARWMC score of 7 or more (HR for any stroke 2.98, 95% CI 1.29 to 6.93; p= 0.011; HR for non-disabling
stroke 6.34, 95% CI 1.45 to 27.71; p= 0.014), but there was no risk difference in patients with an
ARWMC score of < 7.
Findings of the analysis of the effect of baseline characteristics on the risk
of stenting
This analysis has been published in detail elsewhere.45 We examined the influence of baseline patient
characteristics influencing the risk of stroke, MI or death within 30 days of CAS in a regression model,
including only patients allocated to stenting in whom the procedure was actually initiated (per-protocol
analysis). Patients who crossed over to CAS, received CAS after an attempt at endarterectomy or received
medical therapy instead of CAS were excluded. Risk factors were examined using binomial regression. A
multivariable model was developed using a forward stepwise approach. Independent predictors of risk were
age (RR 1.17 per 5 years of age, 95% CI 1.01 to 1.37), a right-sided procedure (RR 0.54, 95% CI 0.32 to
0.91), aspirin and clopidogrel prior to CAS (compared with any other antiplatelet regimen) (RR 0.59,
95% CI 0.36 to 0.98), smoking status and the severity of index event. In patients in whom a stent was
deployed, use of an open-cell stent conferred higher risk than use of a closed-cell stent (RR 1.92, 95% CI
1.11 to 3.33). The use of a cerebral protection device did not modify the risk.
Incidence, impact and predictors of cranial nerve palsy and haematoma
following carotid endarterectomy
This analysis has been published in detail elsewhere.46 We analysed the effects of patient factors and
surgical technique on the risk, and impact on disability, of cranial nerve palsy or haematoma in the surgical
arm, including only patients allocated to endarterectomy in whom the procedure was actually initiated
(per-protocol analysis). Patients who crossed over to CEA, received CEA after an attempt at CAS or received
medical therapy instead of CAS were excluded. Forty-five of 821 (5.5%) patients undergoing CEA
developed cranial nerve palsy, one instance of which was disabling (mRS of 3 at 1 month). Twenty-eight
(3.4%) patients developed severe haematoma; 12 patients with haematoma also had cranial nerve palsy,
a significant association (p< 0.01). Independent risk factors modifying the risk of cranial nerve palsy in the
multivariate analysis were cardiac failure (RR 2.66, 95% CI 1.11 to 6.40), female sex (RR 1.80, 95% CI 1.02
to 3.20), the degree of contralateral carotid stenosis and time from randomisation to treatment > 14 days
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(RR 3.33, 95% CI 1.05 to 10.57). The risk of haematoma was increased in women, by the prescription of
anticoagulant drugs pre-procedure and in patients with atrial fibrillation, and was decreased in patients in
whom a shunt was used and in those with a higher baseline cholesterol level.
Findings of the analysis of the effect of baseline characteristics on the risks
of procedural stroke, myocardial infarction or death after endarterectomy
This analysis has been published in detail elsewhere.47 We examined the influence of baseline patient
characteristics influencing the risk of stroke, MI or death within 30 days of endarterectomy in a regression
model, including only patients allocated CEA in whom the procedure was actually initiated (per-protocol
analysis). Patients who crossed over to CEA, received CEA after an attempt at CAS or received medical
therapy instead of CAS were excluded. Demographic and technical risk factors for these procedural
complications were analysed sequentially in a binomial regression analysis and, subsequently, in a
multivariable model. The risk of stroke, MI or death within 30 days of CEA was higher in female patients
(RR 1.98, 95% CI 1.02 to 3.87; p= 0.05), and with increasing baseline DBP (RR 1.30 for each 10mmHg
increase, 95% CI 1.02 to 1.66; p= 0.04). In a multivariable model, only DBP remained a significant
predictor. The risk was not related to the type of surgical reconstruction, anaesthetic technique or
perioperative medication regimen. A total of 21.2% of events occurred on or after the day of discharge.
Findings of the cost–utility analysis
Resource use and costs
The cost–utility economics analysis has been published elsewhere.48 Mean index procedure duration was
107 minutes [standard deviation (SD) 47 minutes] in the endarterectomy group (n= 700) and 68 minutes
(SD 33 minutes) in the stenting group (n= 691; see Appendix 9). Eighty-two per cent of endarterectomy
patients (n= 794) had general anaesthetic compared with 0% of stenting patients (n= 853). Eighteen per
cent of endarterectomy patients had local anesthetic compared with 100% of stenting patients. In the
endarterectomy group a shunt was used in 40% of patients (n= 818) and a patch in 66% (n= 693). In the
stenting group a stent was deployed in 92% of patients (n= 816) and a cerebral protection device was
used in 71% (n= 824). Sixty-four per cent of endarterectomy patients (n= 813) were admitted to the ICU
post-operatively versus 52% in the stenting group (n= 808). Length of stay on the ward was 5.7 days
(SD 9.4 days) for endarterectomy (n= 803) and 5.1 days (SD 10.8 days) for stenting (n= 789). In patients
randomised to endarterectomy the mean number of additional endarterectomies during follow-up was
0.039 (SD 0.193) and the mean number of stents was 0.023 (SD 0.159). In patients randomised to
stenting, the figures were 0.066 (SD 0.257) and 0.028 (SD 0.172), respectively. No patients in the
endarterectomy group had a fatal MI during the first 30 days after treatment, compared with three
patients in the stenting group; five patients had a non-fatal MI in the endarterectomy group compared
with none in the stenting group; 28 patients in the endarterectomy group had severe haematoma
compared with eight patients in the stenting group; one patient in each group had disabling cranial nerve
palsy. Patients in both groups underwent a range of imaging tests; ultrasound was the most common in
the endarterectomy group (234 tests; n= 857) compared with intra-arterial angiography in the stenting
group (352 tests; n= 853). Drug usage 1 month after treatment was similar for both endarterectomy
(n= 785) and stenting (n= 781) groups. Seventy-one patients (8%) in the endarterectomy group had one
or more strokes during the 5-year time horizon compared with 114 patients (13%) in the stenting group;
a higher proportion of strokes in the stenting group were non-disabling (61% vs. 37%).
Accounting for missing data using multiple imputation, mean total costs per patient were £6762 (95% CI
£6154 to £7369) in the endarterectomy group (n= 857) and £7351 (95% CI £6786 to £7915) in the
stenting group (n= 853) (Table 9). In both groups, approximately two-thirds of the total costs were
for the index procedure and one-third for follow-up. Values were similar for complete-case analysis
(see Appendix 9).
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
Utility values and quality-adjusted life-years
Mean utility values at each follow-up point were similar for the two groups and there was a decline over
time. Accounting for missing data, mean utility values per patient increased from 0.758 (95% CI 0.743 to
0.747) in the endarectomy group at baseline to 0.779 (95% CI 0.763 to 0.795) at 3 months and then
declined to 0.594 (95% CI 0.563 to 0.625) at 5 years (Table 9). In the stenting group, the values were
0.776 (95% CI 0.761 to 0.790) at baseline, 0.777 (95% CI 0.759 to 0.795) at 1 month and 0.609
(95% CI 0.578 to 0.641) at 5 years. Mean total QALYs per patient were 3.228 (95% CI 3.150 to 3.306)
in the endarterectomy group and 3.247 (95% CI 3.160 to 3.333) in the stenting group. Utility values and
QALYs were similar for complete cases (see Appendix 9).
Cost–utility analysis
Mean NMBs for endarterectomy and stenting were £57,793 (95% CI £55,994 to £59,592) and £57,580
(95% CI £55,699 to £59,461) at a maximum willingness to pay for a QALY of £20,000, and £90,070
(95% CI £87,520 to £92,621) and £90,046 (95% CI £87,329 to £92,762) at a maximum willingness to
pay for a QALY of £30,000 (Table 9). In the base-case analysis there were no significant differences in
costs between the two groups (mean incremental costs for stenting versus endarterectomy £537, 95% CI
–£238 to £1312) or in outcomes (mean QALYs gained –0.010, 95% CI –0.117 to 0.097; Table 10).
The incremental NMB for stenting versus endarterectomy was not significantly different from zero at a
maximum willingness to pay for a QALY of £20,000 (mean –£723, 95% CI –£3134 to £1670) or £30,000
(mean –£830, 95% CI –£4265 to £2605).
We repeated the analysis several times using alternative versions of the multiple imputation process using
different random number seeds to investigate if the conclusions of the analysis changed; in every case the
results were qualitatively the same (i.e. there were no significant differences between the two groups in
terms of costs, QALYs and NMBs).
TABLE 9 Mean utility values, QALYs and costs per patient
Variable
Endarterectomy (n= 857) Stenting (n= 853)
Mean 95% CI Mean 95% CI
Cost of index procedure, £ 4558 4319 to 4797 4787 4548 to 5026
Cost of follow-up, £ 2204 1696 to 2711 2563 2114 to 3013
Total cost, £ 6762 6154 to 7369 7351 6786 to 7915
Utility values
Baseline 0.758 0.743 to 0.774 0.776 0.761 to 0.790
3 months 0.779 0.763 to 0.795 0.777 0.759 to 0.795
6 months 0.763 0.746 to 0.780 0.754 0.735 to 0.773
1 year 0.739 0.721 to 0.758 0.737 0.718 to 0.757
2 years 0.709 0.688 to 0.729 0.710 0.689 to 0.732
3 years 0.677 0.655 to 0.699 0.674 0.650 to 0.698
4 years 0.628 0.602 to 0.653 0.648 0.622 to 0.675
5 years 0.594 0.563 to 0.625 0.609 0.578 to 0.641
QALYs 3.228 3.150 to 3.306 3.247 3.160 to 3.333
NMB
£20,000 £57,793 £55,994 to £59,592 £57,580 £55,699 to £59,461
£30,000 £90,070 £87,520 to £92,621 £90,046 £87,329 to £92,762
Costs are in 2013–14 Great British pounds (£). Data include values imputed using multiple imputation. The 95% CIs were
derived from 1000 bootstrap replications of each of the 20 imputed data sets.The NMB is calculated at a maximum
willingness to pay for a QALY of £20,000 and £30,000.
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Sensitivity and subgroup analyses
The cost-effectiveness acceptability curve shows that at a maximum willingness to pay for a QALY of
£20,000 the probability that stenting is cost-effective was 0.27; at a maximum willingness to pay for a
QALY of £30,000 the probability that stenting is cost-effective was 0.31 (Table 10 and Figure 10).
Incremental costs, QALYs gained and incremental NMBs for stenting versus endarterectomy remained not
significantly different from zero when rerunning the base-case analysis without adjustment and using
complete cases (see Table 10). At a maximum willingness to pay for a QALY of £20,000 the incremental
NMB for stenting versus endarterectomy was most sensitive to the cost of stents, cost of operating theatre
time, cost per hospital day and cost of treating stroke (Figure 11), but in every case the incremental NMB
was not significantly different from zero. Similar findings were obtained using a maximum willingness to
pay for a QALY of £30,000 (see Appendix 9). In women and patients aged < 70 years, the mean QALYs
gained from stenting versus endarterectomy were positive, whereas in men and patients ≥ 70 years they
were negative, but in all cases the differences were not significantly different from zero, neither were the
incremental costs and the incremental NMBs.
Future planned analyses
In addition to the data presented in this report further analyses planned include:
l analysis of the carotid artery ‘in-stent’ stenosis measurements with DUS versus computerised
tomography angiography substudy
l analysis of the relation between restenosis and recurrent stroke
l a more detailed analysis of the mRS as an index of disability during follow-up.
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FIGURE 10 Cost-effectiveness acceptability curve. Cost-effectiveness acceptability curve showing the probability
that stenting is cost-effective vs. endarterectomy at different values of the maximum willingness to pay for a
QALY. The probability that endarterectomy is cost-effective is one minus the probability stenting is cost-effective at
each value of the maximum willingness to pay for a QALY.
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Base case
Anaesthesia cost: low
Anaesthesia cost: high
Theatre cost: low
Theatre cost: high
Surgeon and radiologist cost: low
Surgeon and radiologist cost: high
Shunt cost: low
Shunt cost: high
Patch cost: low
Patch cost: high
Stent cost: low
Stent cost: high
Cerebral protection device cost: low
Cerebral protection device cost: high
Cost of other materials used in stenting: low
Cost of other materials used in stenting: high
Cost per hospital day: low
Cost per hospital day: high
Cost per additional carotid artery procedures: low
Cost per additional carotid artery procedures: high
Imaging cost: low
Imaging cost: high
Severe haematoma cost: low
Severe haematoma cost: high
Disabling cranial nerve palsy cost: low
Disabling cranial nerve palsy cost: high
Fatal MI cost: low
Fatal MI cost: high
Non-fatal MI cost: low
Non-fatal MI cost: high
Drug treatment cost: low
Drug treatment cost: high
Cost of treating stroke: low
Cost of treating stroke: high
Discount rate: 1.5%
Discount rate: 5%
–4000 –2000 0 2000
Incremental NMB
(maximum willingness to pay for a QALY = £20,000)
FIGURE 11 Univariate sensitivity analysis. All analyses are as for the base-case analysis with univariate adjustment
of the parameters listed. Results are point estimates of the incremental NMB of stenting vs. endarterectomy
(circles) and 95% CIs (capped spikes). The incremental NMB is calculated at a maximum willingness to pay for a
QALY of £20,000 (see Figure 12 in Appendix 9 for results calculated at a maximum willingness to pay for a QALY
of £30,000).
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Chapter 4 Discussion
Main findings
Carotid artery stenting has a higher short-term (periprocedural) risk than CEA in terms of stroke, but
has a lower rate of MI and severe haematoma, and avoids injury to cranial nerves during endarterectomy.
The additional short-term risk associated with CAS is largely attributable to non-disabling strokes, and the
absolute difference in the risk of any stroke during the whole of follow-up in ICSS was small, with the
47 additional strokes in the stenting group translating to one extra stroke (typically non-disabling) for every
156 patient-years of follow-up. The primary analysis of the trial showed that stenting is equivalent to
endarterectomy in preventing fatal or disabling stroke up to 10 years after treatment. Severe restenosis or
occlusion of the treated carotid artery was rare, with no difference between treatment groups. Stenting also
appeared to be as effective as endarterectomy in preventing ipsilateral stroke occurring during follow-up
after the 30-day procedural period. Importantly, there was no difference in functional outcome of patients
allocated stenting compared with endarterectomy as assessed by the distribution of mRS scores at 1 year,
5 years or the end of follow-up. Moreover, there were no differences in costs or QALYs between
the treatments.
Comparison with other trials
Previous data on prevention of strokes in patients with symptomatic carotid stenosis comparing stenting
with endarectomy have been available from three trials reporting near- and mid-term follow-up only,
two of which had stopped recruitment before reaching the full sample size.49,50
The Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis trial (EVA-3S)
was stopped early because of a significantly lower rate of periprocedural stroke or death in the
endarterectomy group than in the stenting group.25,49 However, it showed no significant differences in
cumulative 4-year rates of fatal or disabling stroke between stenting (6.3%) and endarterectomy (4.0%).51
The Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial in symptomatic patients was
stopped early on grounds of cost and futility, but did not show non-inferiority of stenting compared with
endarterectomy within 30 days after treatment.50 In SPACE, ipsilateral disabling stroke within 2 years, or
death or disabling stroke in any territory within 30 days of treatment, was recorded in 5.7% patients
randomised to stent treatment and in 4.7% of patients allocated to surgery.52
In the Carotid Revascularisation Endarterectomy versus Stenting Trial (CREST), there was a trend of an
increased risk for major ipsilateral stroke in the stent group (1.4%) compared with the endarterectomy
group (0.5%) occurring up to 4 years after treatment (p= 0.05), and including both patients with
symptomatic and asymptomatic carotid stenosis.53 This inclusion of asymptomatic patients in CREST
probably also accounts for the lower overall event rates reported in that trial. The data from ICSS support
these findings; the risk of having a severe stroke remains low after endarterectomy or stenting even after
the first 2–4 years of follow-up and, in ICSS, does not differ between stenting and endarterectomy up
to 10 years after randomisation.
ICSS is also in agreement with other randomised trials that have previously reported increased risks in
procedure-related strokes that did not lead to disability associated with stenting,49,50,53 and in the MRI
substudy of ICSS there was a higher incidence of cerebral infarction 1 month after stenting compared with
endarterectomy, even where this was not associated with a clinical event.44 This excess of periprocedural
non-disabling strokes accounts for the difference in the combined outcome measure of procedural stroke or
death, or stroke in the ipsilateral carotid territory thereafter, in favour of surgery. However, if we consider all
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strokes occurring in the territory of the treated carotid artery after the procedural period, these were no more
frequent after stenting than endarterectomy. It is these strokes that the procedure is designed to prevent
and, in these terms, stenting can be considered to be as effective as surgery. However, we observed a small
increase in risk in non-procedural stroke occurring in the contralateral carotid or vertebrobasilar territory in
the stenting group compared with the endarterectomy group. It is possible that endarterectomy has a
beneficial effect in preventing strokes occurring outside the territory of the revascularised artery, possibly
through improvement in collateral flow. However, the most likely explanation is that the difference in
non-ipsilateral strokes between CAS and CEA in ICSS represents a chance finding.
No other trials have reported the impact of stenting versus endarterectomy on long-term functional
outcome measured using the mRS. We have previously reported that the impact of the excess of
non-disabling stroke on the mRS scores at 30 days after stenting in ICSS patients was balanced by the
impact of the excess of MI, cranial nerve palsy and haematoma on mRS scores after endarterectomy
(data not shown). The fact that there was no long-term difference in the distribution of mRS scores
at 1 year, 5 years and at the end of follow-up implies that the differences in the various outcomes,
including stroke, between the two treatments also balance each other in the long term.
Secondary outcomes and substudies
Restenosis
The SPACE trial reported higher cumulative rates of severe restenosis 2 years after stenting (10.7%)
compared with the endarterectomy group (4.6%).52 In contrast, there was no significant difference in
severe restenosis between stenting and endarterectomy in the EVA-3S trial at 3 years (3.3% vs. 2.8%), nor
in CREST at 2 years (6.0% vs. 6.3%).54,55 ICSS with cumulative 5-year rates of 11.8% and 8.6% for CAS
and CEA, respectively, supports the view that completed stent treatment is as effective as endarterectomy
in preventing residual or recurrent narrowing or occlusion of the carotid artery.
White-matter lesions and periprocedural stroke risk
Carotid artery stenting was associated with a higher risk of stroke compared with CEA in patients with an
ARWMC score of 7 or more, but there was no risk difference in patients with an ARWMC score of < 7.30
This implies that the presence of white-matter lesions on brain imaging should be taken into account
when selecting patients for CAS, which should be avoided in patients with extensive white-matter lesions,
but might be an acceptable alternative to CEA in patients with less-extensive lesions.
Magnetic resonance imaging substudy
Approximately three times more patients in the stenting group than in the endarterectomy group had new
ischaemic lesions on DWI on post-treatment scans.44 This suggests that the difference in periprocedural
clinical stroke risk in ICSS is not likely to have been caused by ascertainment bias. In fact, there is a higher
incidence of ischaemic lesions seen on MRI than of recorded clinical events (stroke/TIA). Whether these
excess ‘silent’ lesions have any functional consequence for the patient (e.g. cognitive impairment or
increased susceptibility to vascular dementia) is an issue not addressed by ICSS, but the fact that there was
no difference in functional outcome between the two treatment groups makes it unlikely that the excess
of ‘silent’ lesions had any long-term consequences.
Subgroup analysis of procedural events
An exploratory analyses of the composite outcome of stroke, death or procedural MI for pre-defined
subgroups suggested that carotid stenting might have a similar risk to endarterectomy in women, but that
the intervention was more hazardous than endarterectomy in men. However, the difference between the
HRs comparing the risk of stenting with endarterectomy in men and women only reached borderline
significance (interaction p= 0.071). Stenting was more hazardous, and endarterectomy less hazardous,
in patients not taking medication for hypertension at baseline than in patients taking medication
for hypertension.
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Subgroup analysis: long-term primary outcome
Exploratory subgroup analyses showed no significant modification of the HR of the primary outcome event
or of the combined outcome of procedural death or stroke or non-procedural ipsilateral stroke by any of
the evaluated variables.
Cost–utility analysis
Our economic analysis showed that stenting and endarterectomy had similar costs (index procedure costs,
follow-up costs and total costs) and outcomes (utility values, QALYs). This was despite the finding in the
trial of higher rates of non-disabling strokes in the stenting group. Comprehensive sensitivity analyses
showed little uncertainty in this finding. Non-significant differences in utility values and QALYs mirror
differences in mRS scores and all-cause mortality found in the trial. The findings mean that there is no
reason to prefer either stenting or endarterectomy on the basis of differences in quality of life or on
economic grounds; other factors should be taken into account when deciding which option to use to treat
patients with symptomatic carotid stenosis (e.g. the age of the patient or imaging features).
Strengths, weaknesses and generalisability
Because of the nature of the interventions in ICSS, it is not possible for either patients or researchers to be
blinded to allocated treatment. However, the Chief Investigator and the steering committee remained
blinded to the cumulative event rate throughout the trial and the outcome events that were independently
assessed according to the following procedure: the events were documented in detail by the investigating
centre, censored after receipt at the central office to remove clues as to the treatment allocated, and then
adjudicated by an independent neurologist. Furthermore, the results of the imaging substudies were all
assessed blinded to treatment.
A range of imaging techniques, including DUS, was allowed in the trial to assess the degree of carotid
stenosis prior to randomisation, according to standard practice at the specific centre. Bilateral DUS scan
alone was allowed by the protocol only if it was standard practice to treat on the basis of ultrasound alone
in individual centres. The number of patients not having a procedure initiated because initial imaging
appeared to have misclassified the severity of the stenosis was low (three patients in the CAS arm and one
in the CEA arm were found to have < 50% stenosis after randomisation). Fourteen patients did not have
a procedure because the stenosis was found to have progressed to occlusion after randomisation
(five patients in the CAS arm and nine in the CEA arm). A number of initiated stenting procedures were
aborted because the stenosis was found to be < 50% (seven cases) or occlusion was found to be present
(15 cases) when angiography was performed immediately prior to attempting to place the stent. Obviously
such cases would not have been detected in surgical patients, where the procedure would have gone
ahead without knowledge of the exact degree of stenosis immediately prior to the surgery. We can
assume, therefore, that the total rate of stenosis found to be inappropriate at procedure in the trial is
accurately reflected by the figures for the stenting arm [i.e. a total of 10 cases found to have < 50%
stenosis (1.2% of 853 patients randomised to stenting) and perhaps also the 20 cases of occlusion
(2.3%)]. However, the proportion of patients who developed occlusion after randomisation (and who were
therefore appropriately randomised) is unknown. Thus, despite the leeway allowed in the approach to
measuring baseline stenosis in ICSS, at least 96.5% of patients were correctly identified in terms of their
degree of stenosis as being suitable for inclusion in the trial (50–99%).
Inevitably in ICSS, which started when stenting was a relatively new treatment, the experience of the
interventionists in carotid stenting was less than that of the surgeons in CEA. However, the risk of outcome
events associated with stenting was lower in inexperienced, supervised centres than in more experienced
centres (see Figure 4) and there was no significant difference in the excess hazard of stenting compared
with endarterectomy between supervised and experienced centres, or between centres recruiting more or
less than 50 patients; therefore, inexperience is not a major determinant of our results. However, the HR
was lower among patients treated at the larger centres than in the smaller centres, which might indicate
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some effect of procedural volume on technical expertise. A pooled analysis of stenting outcomes by the
Carotid Stenting Trialists’ Collaboration showed lower procedural stroke or death risks among patients
treated by interventionists with higher annual in-trial procedure volumes, indicating that regular practice in
carrying out the procedure matters more than individual total experience or centre volumes.56
The trial was an international, multicentre study, so patients were included at centres with a range of
experience (above the minimum necessary for trial entry) and standards of practice, and a variety of stents
and protection devices were used in the trial. Overall, this should mean that the results of ICSS may be
taken as being widely applicable in patients and at centres who match the criteria for inclusion in
the study.
In terms of the cost–utility analysis, the main strength is that it is based on a large, international,
multicentre, randomised trial with detailed information on resource use, utility values and mortality for a
median follow-up period of 4.2 years. There are several limitations. First, data on costs of managing
strokes were not collected in the trial. However, rather than simply extrapolating from averaged external
cost data for stroke, as is done in the vast majority of health economic analyses of large trial cohorts, given
the specific nature of the strokes occurring in our particular population, we used individual patient data
from the OXVASC study to predict these costs at the patient-level. These were, therefore, detailed
contemporaneous UK-specific costs matched to patients in the trial according to significant cost drivers,
and blinded as to treatment allocation, but they do not reflect the actual costs incurred by each patient.
Nevertheless, when we adjusted these costs in sensitivity analyses the results did not change appreciably.
Second, the analysis took a UK NHS/PSS perspective on costs, and utility values were calculated using a UK
population value set. Results may differ for other countries depending on the relative value of unit costs
and the value set used to generate utility values. Third, a wider perspective (e.g. societal) could have
been taken to measure costs, including impacts on the rest of society, including patients, families and
businesses. Given that the trial found no differences in mortality or disability, it is unlikely that this would
affect the incremental costs, although total costs associated with each treatment may change. Fourth, the
time horizon was 5 years. We could have taken a longer time horizon, but there were no differences in
costs or benefits between groups at this point, so this would not have affected the results of the
incremental analyses.
Implications for health care
Stroke is the major cause of acquired adult physical disability and is responsible for 12% of all deaths in
the UK. Atherosclerotic stenosis of the carotid artery is an important cause of stroke, and the risk of
recurrent stroke in recently symptomatic patients with severe carotid stenosis is as high as 28% over
2 years. Therefore, revascularisation offers an important means to reduce the burden of stroke in the
population. The results of ICSS taken with those of other trials demonstrate that CAS is as effective as
endarterectomy in preventing ipsilateral stroke during long-term follow-up. Carotid stenting carries a
higher risk of periprocedural stroke, which is largely accounted for by an excess of non-disabling stroke,
and more patients in the stenting group than in the endarterectomy group had new ischaemic lesions on
post-treatment MRI scans. This excess of non-disabling stroke and new lesions associated with stenting
does not translate into a significant difference between stenting and endarterectomy in long-term
functional outcomes as assessed by the mRS, quality of life as assessed by the EQ-5D-3L, or a difference
in costs as assessed by the economics analysis. The mRS is not a precise measure of the level of
independence, and we cannot rule out subtle differences in cognitive outcome or subjective perception
of wellbeing between the two treatment groups not captured by these scales. However, it is notable
that a substudy of ICSS, carried out at two ICSS centres in which 177 patients enrolled in ICSS had
detailed neuropsychological examination, showed no significant difference in cognition 6 months after
stenting compared with endarterectomy, despite double the number of new ischaemic lesions on MRI
after stenting.57 Thus, the evidence from ICSS indicates that any impact of the excess of non-disabling
stroke and asymptomatic infarction associated with stenting is limited and short-lasting.
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We have shown that the severity of white-matter disease is an important modifier of risk with stenting, but
not with endarterectomy. In a separate analysis restricted to ICSS patients who were randomised to and
completed stenting treatment, age was an independent predictor of the risk of stroke, MI or death within
30 days of stenting. In an analysis of CREST, age also significantly modified the risk of stenting versus
endarterectomy,53 whereas a pooled analysis of the data from ICSS with data from EVA-3S and SPACE, as
well as a meta-analysis of all the existing trials, have confirmed that patients over the age of 70 years have
a higher risk of stroke or death with stenting, but patients below the age of 70 have a similar risk with
stenting compared with endarterectomy.58,59
The analysis of the risk of baseline and procedural-related factors in ICSS showed that the use of an
open-cell stent conferred higher risk than use of a closed-cell stent (RR 1.92, 95% CI 1.11 to 3.33),
but the use of a cerebral protection device did not modify the risk. Although this was not a randomised
comparison, the findings are in keeping with results from the SPACE study and large observational
studies.60,61 This effect of stent design may reflect the benefit of closed-cell stents providing greater
coverage of the atheromatous lesion and implies that, in general, closed-cell stents should be preferred
to open-cell stents.
The multivariate analysis showed that DBP at baseline was a significant predictor of the risk of stroke, MI
or death within 30 days of CEA, implying that control of hypertension pre-operatively is an important
aspect of ensuring the safety of surgery. Our analysis confirmed that cranial nerve palsy remains an
important complication of endarterectomy, but cranial nerve palsy recovered in almost all patients. Thus,
the risk of cranial nerve injury should not influence the choice between CAS and CEA in patients who have
not had previous carotid surgery, unless other features favour stenting.
We therefore conclude that the data from ICSS together with data from the other randomised trials show
that the choice between stenting and endarterectomy should take into account the different procedural
risks of these treatments related to individual patient characteristics. Endarterectomy remains the treatment
of choice for older patients and those with extensive white-matter disease, but stenting is an appropriate
treatment alternative for patients with symptomatic carotid stenosis if the risk of periprocedural stroke is
low, for example in younger patients and those with lower levels of pre-existing white-matter disease.
Such patients should be offered stenting after informed consent giving full consideration of the overall
periprocedural risks. Considerations of cost and cost-effectiveness should not affect the decision about
which of these two treatments to use. In addition to taking into account clinical and imaging features,
treatment decisions should take into account patient preferences, with reference to the differing nature of
the risks with the two procedures.
Implications for research
The impact of the treatments on patients’ cognitive function was not assessed as part of the main protocol
in ICSS (or any of the other reported trials). Given the effect of stenting on silent infarction noted in ICSS
MRI substudy, measurement of cognitive function should be an important part of any future study of
stenting and/or CEA as this might be an important consideration in choosing between stenting
and endarterectomy.
Other important areas for future studies include assessing the morphology and stability of the carotid
plaque using modern imaging techniques prior to intervention, and identifying the clinical characteristics
of patients that determine how likely they are to benefit from revascularisation in the context of modern
optimised medical therapy in lower-risk symptomatic and asymptomatic patients.
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Appendix 1 Consent form
CONSENT FORM  
Patient ID for this trial __ __ __ __  Centre Number __ __ __ __ __  Project ID__ __ __ __ 
Title of project: International Carotid Stenting Study (ICSS)  
Name of researcher:  
Please initial 
box  
1) I confirm that I have read and understood the information sheet dated  
19/07/2004 (version 2.21) for the above study and have had the 
opportunity to ask questions. 
 
2) I confirm that I have had sufficient time to consider whether or not I want  
to be included in the study. 
 
3)  I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving any reason, without my medical  
care or legal rights being affected. 
 
4)  I understand that sections of any of my medical notes may be looked at by  
responsible individuals from regulatory authorities where it is relevant to  
my taking part in research. I give permission for these individuals to have  
access to my records.  
 
5)  I understand that information held by the NHS and records maintained by  
the General Register Office may be used to keep in touch with me and  
follow up my health status 
 
6)  I agree to take part in this study.  
____________________   ______________________  ___________________________ 
Name of Patient     Date     Signature  
 
___________________ ______________________  ___________________________ 
Name of Person taking consent   Date     Signature 
 (if different from researcher)  
 
_______________ ___________________ ______________________ 
Researcher Date      Signature  
 
1 copy for patient, 1 copy for researcher, 1 copy to be kept with hospital notes  
Version 2.21 31/10/04  
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Appendix 2 Patient information sheet
International Carotid Stenting Study (ICSS) 
 
You are invited to participate in a research project we are running to compare the risks and benefits of 
two treatments for carotid artery narrowing. Before you decide it is important for you to understand 
why the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
What is the purpose of the study? Narrowing of one of the carotid arteries in the neck, which supply 
blood to the brain, is an important cause of stroke. It is therefore important to remove this narrowing to  
prevent stroke. The traditional method of treatment is a surgical operation (endarterectomy), often 
performed under a general anaesthetic, in which the diseased part of the artery is cut out through an 
incision in the neck. We are studying a new treatment in which is a small tube made of wire mesh, 
called a stent, is placed inside the narrowed artery in the neck. The stent is placed into the artery 
through a small tube (catheter) inserted in the groin under local anaesthetic. Injections of dye will be 
made through the catheter to take Xray pictures of the narrowing. This is called angiography. Once in 
position across the narrowing the stent is opened out where it acts like a spring to keep the artery open. 
This new treatment is known as carotid artery stenting. Stenting has been used successfully in the 
arteries supplying the heart and the legs. Stenting avoids the discomforts of surgery and risks of general 
anaesthesia but we do not know which treatment is better overall for the patient.  
Why I have I been chosen? You have been chosen because the tests that you have had reveal you may 
benefit from either surgery or the insertion of a stent.  
Do I have to take part? Your participation in the trial is entirely voluntary. It is up to you to decide 
whether or not to take part. If you do decide to take part you will be given this information sheet to 
keep and be asked to sign a consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. This will not affect the standard of care you receive. 
What will happen to me if I take part? To find out which treatment is better, half the patients 
entering the study will be allocated to be treated with surgery and the other half to be treated by 
stenting. The treatment is allocated by a computer, which chooses the treatment for each individual by 
chance. This will allow us to compare the benefits and risks of the two treatments fairly. All patients 
entering the study will receive the best possible medical treatment, including aspirin or similar tablets, 
if tolerated, and careful treatment of high blood pressure or raised blood fats. If you agree to join the 
study your GP will be informed and you will be seen by a neurologist approximately 30 days after your 
treatment, after six months and then annually after entering the study for up to 5 years. At each visit a 
carotid ultrasound (a non-invasive sound picture of the arteries which does not use radiation) will be 
performed to assess the degree of narrowing. You will be asked to fill in a questionnaire about your 
health and how you feel about yourself before your allocated treatment and at follow-up visits.  
What will happen if I am allocated surgery? You will be scheduled to have surgery as soon as 
routinely possible and the operation will be performed by an experienced surgical team. You may need 
to have a general anaesthetic to put you to sleep during the operation. An angiogram may be  
performed before or after the procedure. You will usually have to stay in hospital for several days after 
surgery. 
What will happen if I am allocated carotid stenting? You will have a fine wire and tube inserted 
into an artery in the groin, which will be used to feed the stent up the ar tery and into the neck, so that it 
can be placed across the narrowing in the carotid artery. This is normally done following a local 
anaesthetic injection into the groin area, but you will stay awake during the procedure. A balloon or 
filter device may also be fed up the artery to collect any debris that may be dislodged during the 
stenting procedure. X ray pictures (angiography) will taken immediately before, during and after 
stenting the artery to make sure the wire and stent are in the correct place. In a small percentage of 
patients, the angiography may show that stenting is not possible. In this case, you will be referred for 
surgery instead. If you are well after the stenting procedure you will be able to go home the day 
afterwards. 
What are the possible disadvantages and risks of taking part? Both surgical endarterectomy and 
stenting carry a risk of causing a stroke at the time of the treatment. Previous trials showed a significant 
risk of stroke or death at the time of surgery or stenting of between 6 and 10 in every 100 patients. 
There is a small risk of about one in a hundred that angiography will cause a stroke. Stroke caused by 
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surgery, stenting or angiography may recover, cause permanent disablement or be fatal. However, you 
are being considered for the study because the risks of strokes resulting from surgical or stenting 
treatment are believed to be less than leaving the carotid artery narrowing untreated. Treatment is not 
always successful and the narrowing may recur and require further treatment or the artery may become 
blocked. 
What are the other main risks of surgery? Surgery also has a risk of causing a heart attack. About 
one in ten patients has temporary tongue or facial weakness. A large blood clot (haematoma) may form  
at the site of incision, which may require removal. Surgery results in a permanent scar in the neck.  
What are the other main risks of stenting? Angiography and stenting may also result in bruising or 
haematoma at the site of injection (usually in the groin) and can cause temporary discomfort or pain in 
the neck. There is a small risk of allergic reactions to the dye. 
What are the possible benefits of taking part? All patients taking part in the trial will receive careful 
follow-up and the opportunity to benefit from advances in treatment. Overall, treating carotid 
narrowing will reduce your chances of subsequent strokes. 
What if something goes wrong? If you are harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to someone’s negligence, then you may 
have grounds for taking legal action but you may have to pay the legal costs. Regardless of this, if you 
wish to complain, or have any concerns about this study, the normal National Health Service 
complaints mechanism should be available to you. 
Will my taking part in this study be kept confidential? Information relevant to your medical 
condition will be collected as part of the study. Medical information about yourself and your treatment 
will be kept in the central study office in the Institute of Neurology, University College London, 
England for analysis. Professor Martin M Brown, the Principal Investigator, will be responsible for the 
security and access to the information. All information regarding your medical records will be treated 
as strictly confidential and will only be used for medical research on the factors that influence the 
diagnosis of or outcome from stroke. The data may be used for future research on stroke by other 
research institutions in the UK but again your confidence will be strictly maintained. Your medical 
records may be inspected by competent authorities and properly authorised persons, but if any 
information is released outside the trial office this will be done so in coded form with your name 
removed from the records so that your confidentiality is strictly maintained. The results of the study 
will be published in medical journals or other public sites. Information regarding the study will be 
stored on a secured computer database for a minimum of 15 years. 
Who is organizing and funding the study? The study is organized by the Stroke Research Unit at the 
Institute of Neurology, UCL and funded by grants from The Stroke Association, Sanofi Synthelabo and  
the European Union. 
Who has reviewed the study?   The NorthWest Multi-Centre Research Ethics Committee reviewed 
this study. 
Thank you for taking time to consider participating in this study. If you agree to take part, you 
will be given a copy of this information sheet and a copy of the signed consent form. 
Further information can be obtained from: 
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Appendix 3 International Carotid Stenting Study
follow-up form
ICSS FOLLOW UP FORM 
(Please ask the patient to complete form EQ5D at same time) 
Centre ....................................... Investigator ......................................         ICSS No __ __ __ __ 
Family Name .................................... Forename .........................................         D o B __ __/__ __/__ __ 
                    day/month/year 
Follow up (time since randomisation):   1mth     6mth     1yr     2yr     3yr     4yr     5yr   
          Extra  
(follow up dates should be  calculated from date of randomisation 
except one month which is calculated from date of treatment) 
Date of follow up  __ __/__ __/__ __ 
        
    EVENTS SINCE LAST FOLLOW UP 
                   Date most recent      Duration of symptoms 
                 Yes  No              day/month/year (999 if persisting) 
Death             __ __/__ __/__ __ 
Left carotid ischaemic stroke (symptoms >24hrs)*       __ __/__ __/__ __ __ __ __ days 
Right carotid ischaemic stroke (symptoms >24hrs)*      __ __/__ __/__ __ __ __ __ days 
Vertebrobasilar ischaemic stroke (symptoms >24hrs)*      __ __/__ __/__ __ __ __ __ days 
Left retinal infarction. (symptoms >24hrs)*       __ __/__ __/__ __ __ __ __ days 
Right retinal infarction (symptoms >24hrs)*       __ __/__ __/__ __ __ __ __ days 
Intracerebral haemorrhage (symptoms >24hrs)*      __ __/__ __/__ __ __ __ __ days 
Subarachnoid haemorrhage (symptoms >24hrs)*      __ __/__ __/__ __ __ __ __ days 
Left carotid TIA  (symptoms <24hrs)        __ __/__ __/__ __ 
Right carotid TIA (symptoms <24hrs)       __ __/__ __/__ __ 
Vertebrobasilar TIA (symptoms<24hrs)       __ __/__ __/__ __ 
Left carotid amaurosis fugax (symptoms <24hrs)      __ __/__ __/__ __ 
Right carotid amaurosis fugax (symptoms<24hrs)      __ __/__ __/__ __ 
Non fatal M I**          __ __/__ __/__ __ 
Other medical events (give details)        __ __/__ __/__ __ 
Details .................................................................................. 
 Please complete death report   
* Please complete major event report,   **complete major event report if within 30 days of stenting/surgery  
 
Modified RANKIN on day of follow up:  
0    Asymptomatic 
1    Non-disabling symptoms which do not interfere with lifestyle 
2    Minor disability-symptoms which lead to some restriction in lifestyle but do not interfere with the  
patients capacity to look after themselves. 
3    Moderate disability-symptoms which significantly interfere with lifestyle or prevent totally  
independent existence, but able to walk without assistance. 
4    Moderately severe disability-symptoms which clearly prevent independent existence. Unable to walk without     
assistance but does not need constant attention day and night.     
5    Severely disabled-totally dependent requiring constant attention day and night. 
6    Dead 
Is any disability rated above caused by medical condition/s other than stroke  Yes   No   
If Yes  give details………………………………………………………………………… 
  Yes No 
Smoking currently      
Blood pressure  Systolic __ __ __ mmHg       Diastolic __ __ __ mm Hg 
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ICSS No __ __ __ __ 
PROCEDURES PERFORMED SINCE LAST FOLLOW UP (OR RANDOMISATION IF 1 MONTH FOLLOW UP) 
         Date performed 
                 Yes  No  day/month/year 
Left carotid endarterectomy*        __ __/__ __/__ __ 
Right carotid endarterectomy*        __ __/__ __/__ __ 
Left carotid angioplasty/stenting**        __ __/__ __/__ __ 
Right carotid angioplasty/stenting **        __ __/__ __/__ __ 
Left vertebral angioplasty/stenting **       __ __/__ __/__ __ 
Right vertebral angioplasty/stenting **       __ __/__ __/__ __ 
Other surgery (give details)         __ __/__ __/__ __  Details................. 
.……………………………………………………………………………………………………………. 
*   Ensure surgery technical data form is completed  
 
MEDICATION AT TIME OF FOLLOW UP:  
Warfarin            Heparin     Aspirin         Ticlopidone        Clopidogrel    
  Dipyridamole   Other anticoagulant/antiplatelet agent  (specify) ………… 
Statin therapy  
Antihypertensive treatment  
 
IMAGING - N.B. CAROTID ULTRASOUND SHOULD BE PERFORMED ANNUALLY: 
          Date 
      Yes No   day/month/year 
Carotid Ultrasound performed       __ __/__ __/__ __ 
CT performed         __ __/__ __/__ __ 
MRI performed         __ __/__ __/__ __ 
Angiography  IA        __ __/__ __/__ __ 
  IVDSA        __ __/__ __/__ __ 
  MRA (non-enhanced)      __ __/__ __/__ __ 
  CEMRA       __ __/__ __/__ __ 
  CTA         __ __/__ __/__ __ 
Please send copy of all FILMS and REPORTS to ICSS office  
 
                   Yes  
Now please check  patient has completed form EQ5D     
 
Please arrange next follow up appointment – this should be 6 months after randomisation then at annual intervals 
calculated from randomisation date. If patient has a stroke during follow up please arrange extra follow up 
appointments 30 days and 6 months after the event. 
                      Yes No 
Next appointment arranged       
 
Form completed by (PRINT)..........................................................................Date __ __/__ __/__ __   
                                   day/month/year 
 
PLEASE COPY FOR YOUR FILES THEN POST OR FAX THIS FORM TO THE ICSS OFFICE 
TOGETHER WITH COPIES OF THE EQ5D AND ANY RELEVANT IMAGING FILMS AND/OR REPORTS. 
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Appendix 4 International Carotid Stenting Study
ultrasound form
ICSS ULTRASOUND FORM 
 
 
Centre    
 
Investigator    
 
ICSS No  __ __ __ __ 
 
Patient’s Family Name    Forename       
 
Patient’s DoB __ __/__ __/__ __ 
                        day/month/year 
 
DATE OF ULTRASOUND: __ __/__ __/__ __ 
                          day/month/year 
 
Form completed by (PRINT)           Date __ __/__ 
__/__ __ 
                        
day/month/year 
 
PLEASE POST OR FAX THIS FORM TO THE ICSS OFFICE 
TOGETHER WITH COPIES OF THE ULTRASOUND REPORT 
 
Page 1 of 1                       Version 
2.00- 030703 
 Right carotid artery Left carotid artery 
CCA PSV   
ICA PSV   
ICA EDV   
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Appendix 5 Major event report
ICSS MAJOR EVENT REPORT 
(Stroke or Myocardial infarction)  
Please complete this form, AS WELL AS A FOLLOW UP FORM, for any patient having a stroke or MI  
Centre .............................................. Investigator ...................................... ICSS No __ __ __ __  
Family Name ........................................... Forename ......................................D o B __ __/__ __/__ __ 
day/month/year 
Please complete all sections as appropriate.  
STROKE REPORT 
Date of onset  day__ __/month__ __/year__ __ 
Was the stroke: Non-fatal  Fatal  (complete death report) 
Pathology of stroke Yes  No 
Was CT/MRI scan done to confirm diagnosis    
Ischaemic stroke1    
Intracerebral haemorrhage   
Subarachnoid haemorrhage   
Subdural haematoma   
1If stroke was ischaemic then please give classification, TOAST Criteria (please tick one box): 
Large vessel atherosclerosis     
Small-vessel occlusion (lacunar)   
Cardioembolic    
Other determined cause   Give details of 
type……………………………… 
Unknown cause  
NB Haemrrhagic transformation of an initial infarction should be classified as an ischaemic stroke 
  
Precipitating Events (please tick probable event): 
Complication of angiography  
Complication of carotid procedure (surgery or stenting)  
Hypotension or cardiac arrhythmia  
Territory of stroke (please tick probable territory, or territories - if more than one): 
Right retinal/ophthalmic artery  
Left retinal/opthalmic artery  
Right middle or anterior cerebral artery  
Left middle or anterior cerebral artery  
Right posterior cerebral artery  
Left posterior cerebral artery  
Vertebrobasilar artery (excluding posterior cerebral artery)  
Unknown territory  
HYPERPERFUSION SYNDROME 
Was syndrome    non fatal    fatal  (Please complete death report) 
Was syndrome complicated by stroke               Yes   No 
   
If yes complete section above for stroke 
IMAGING PERFORMED AFTER STROKE ONSET OR HYPER PERFUSION SYNDROME: 
Date 
Yes No day/month/year 
Carotid Ultrasound performed    __ __/__ __/__ __ 
CT performed    __ __/__ __/__ __ 
MRI performed    __ __/__ __/__ __ 
Angiography IA    __ __/__ __/__ __ 
IVDSA    __ __/__ __/__ __ 
MRA (non-enhanced)    __ __/__ __/__ __ 
CEMRA    __ __/__ __/__ __ 
CTA     __ __/__ __/__ __ 
Please send copy of all FILMS and REPORTS to ICSS office  
Page 1 of 2 Version 2.11-
180804
ICSS No __ __ __ __   
DOI: 10.3310/hta20200 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 20
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Featherstone et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
Modified RANKIN scale at 30 days after event (estimate if not seen then): Date:__/__/__ :  
0    Asymptomatic 
1    Non-disabling symptoms which do not interfere with lifestyle 
2    Minor disability-symptoms which lead to some restriction in lifestyle but do not interfere with the  
 patients capacity to look after themselves. 
3    Moderate disability-symptoms which significantly interfere with lifestyle or prevent totally  
 independent existence, but able to walk without assistance. 
4    Moderately severe disability-symptoms which clearly prevent independent existence. Unable to walk 
without assistance but does not need constant attention day and night.   
  
5    Severely disabled-totally dependent requiring constant attention day and night 
6    Dead 
Is any disability rated above caused by medical condition/s other than stroke  Yes   No   
If Yes  give details………………………………………………………………………………………… 
Was the patient seen more than 6 months after event     Yes   No  
If yes give modified Rankin score at 6 months (estimate if not seen then) 
1   2   3   4   5   6  
If No please schedule follow up for 6 months after stroke onset 
 
MYOCARDIAL INFARCTION REPORT     Date of event __ __/__ __/__ __    
Was MI:  Non-fatal   Fatal   (please complete death report) 
 
       Yes No 
Cardiac enzymes elevated 2x normal      
Chest discomfort for >than 30 minutes      
Diagnostic ECG        
Other reasons for diagnosis       If yes give 
details……………………….. 
NB. Two out of three of above required for diagnosis (see protocol)  
 
Description of outcome event: Please give brief description of onset, duration and results of relevant 
investigations especially CT and MRA findings and any evidence indicating aetiology. If stroke occurred within 
thirty days of surgery or stenting please describe;  
1) If anything unusual was noted (e.g. blood pressure, results of monitoring etc.) 
2) Exactly what was being done when the stroke occurred if it did so during the procedure 
3) Whether the stroke could be attributed to any particular technical factor or complication 
…………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………
……………………………………………… 
 
 
Form completed by (PRINT) ................................................................................. Date __ __/__ __/__ __ 
 
PLEASE COPY FOR YOUR FILES THEN POST OR FAX THIS FORM TO THE ICSS OFFICE 
TOGETHER WITH COPIES OF ANY RELEVANT IMAGING FILMS AND/OR REPORTS. 
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Appendix 6 Death report
ICSS Death Report 
 
Centre .............................................. Investigator ...................................... ICSS No __ __ __ __  
Family Name ........................................... Forename .........................................D o B __ __/__ __/__ __ 
                        
 day/month/year 
Date of Death  __ __/ __ __/ __ __ 
     Day /Month /Year 
 
Underlying cause of death (main event leading to death) 
 Tick 
Stroke   (complete major event form) 
Myocardial Infarction     (complete major event form if within 30 days 
surgery/stenting) 
Sudden death, probably cardiovascular      
Pulmonary embolism    
Other vascular (e.g. aortic aneurism)        Details: 
……………………………………………………… 
………………………………………………………………………………………………….……………………
…………………………………………………………………………….…………………………………………
………………………………………………………………………………………………. 
Non-vascular cause Details: 
………………………………………………………… 
………………………………………………………………………………………………….……………………
…………………………………………………………………………….………………………… 
 
Brief description of events leading to death:……………………………………………………………... 
…………………………………………………………………………………………………..……………………
……………………………………………………………………………..…………………………………………
………………………………………………………..………………………………………………………………
…………………………………..……………………………………………………………………………………
……………..…………………………………………………………………………………………………………
……………………………………………………………………….. 
 
Documentation 
Was post-mortem examination (autopsy) performed?  Yes    (please enclose PM/autopsy report)   No    
Please obtain copies of death certificate (please translate into English, if relevant) 
Diagnosis on death certificate: 
1. Primary cause of death  ………………………………………………………… 
2. Contributing cause of death ………………………………………………………… 
 
Form completed by (PRINT): …………………………………………. Date: __ __/ __ __/ __ __ 
          
 Day/month/year 
 
PLEASE COPY FOR YOUR FILES THEN POST OR FAX THIS FORM TO THE ICSS OFFICE 
TOGETHER WITH COPIES ANY RELEVANT IMAGING FILMS AND/OR REPORTS. 
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Appendix 8 Protocol amendment details
O riginal ethical approval for ICSS was received on 4 October 2000 and randomisation commenced inMay 2001 using protocol version 2.00.
Protocol Version 3.1 was introduced after receiving ethical approval on 31 October 2003. The main
changes from version 2.00 were:
l The rules governing proctoring and probationary centres, in particular under what conditions a centre
may make the transition from probationary to full, were made more explicit.
l The inclusion criteria were clarified (making it explicit that it is atheromatous stenosis being studied)
and modified (the degree of stenosis warranting treatment set at 50% or greater by the NASCET
criteria) to reflect current generally accepted practice in the assessment and treatment of stenosis.
l The nature of symptomatic disease in the inclusion criteria was defined so that: ‘Symptoms must have
occurred in the 12 months before randomisation. It is recommended that the time between symptoms
and randomisation should be less than 6 months, but patients with symptoms occurring between
6 and 12 months may be included if the randomising physician considers treatment indicated.’
l Exclusion criteria were extended to include non-atheromatous disease, previously treated artery,
planned major surgery (especially CABG) within 1 month of proposed carotid intervention, or planned
common carotid surgery.
l Procedures for dealing with suspected problems with surgical or stenting technique at individual
centres were included in the protocol.
l The projected sample size was reduced from 2000 to 1500.
l For the primary outcome measure the wording was altered to clarify that non-stroke deaths will be
censored in the primary outcome analysis.
l The EQ-5D-3L became the only measure of quality of life – the Short Form questionnaire-36 items
(SF-36) was dropped. Details of the arrangements for payments to centres and the responsibilities of
centres with regard to indemnity were included.
Protocol Version 3.2 was introduced after receiving ethical approval on 22 November 2007. The main
changes from version 3.10 were:
l Sample size: the protocol was clarified to make it plain that 1500 patients will be enrolled at full
centres – data from patients enrolled at probationary centres to be analysed separately.
l The duration of follow-up will now exceed 5 years for some patients: at the 5-year follow-up, patients
will be asked if they are willing to continue follow-up, in which case annual follow-up will continue up
to a maximum of 10 years from randomisation.
l Two substudies were appended to the main protocol: a restenosis substudy involving an additional
investigation (computerised tomography angiography of the carotid) at 1 year after randomisation and
a MRI substudy involving three MRI investigations (one before and two after treatment). Consent
and patient information forms for these substudies were included with this notification.
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Appendix 9 Further details of the cost–utility
analysis
1. Prediction of hospital and care home costs in ICSS stroke patients using OXVASC study data.
2. Summary of data used in cost–utility analysis.
3. Additional results for univariate sensitivity analysis.
4. Consolidated Health Economic Evaluation Reporting Standards statement.
Prediction of hospital and care home costs in the International
Carotid Stenting Study stroke patients using Oxford Vascular
study data
Hospital and care home costs for patients who had one or more strokes in ICSS were predicted using the
results from multivariate regression analyses aimed at determining the predictors of hospital and care
home costs in patients enrolled in the OXVASC study.36,37
Oxford Vascular study
The OXVASC study population comprises over 91,000 patients registered in nine general practices across
Oxfordshire, UK. Briefly, patient registration began on April 2002 and is ongoing. Only consenting TIA or
stroke patients recruited from 1 April 2002 to 31 March 2007 were included in this analysis.
Patients were followed up from the first TIA or stroke in the study period for which the patient sought
medical attention, referred to here as the index event. Surviving patients were followed up by a research
nurse at 1, 6, 12, 24 and 60 months after the event. Data were collected on patients’ living arrangements,
risk factor changes and disability (measured using the mRS). Patients were also followed up via their general
practitioner and hospital records, recurrent vascular events were identified by ongoing ascertainment, and
all patients had mortality follow-up.
Impairment was measured using the National Institutes of Health Stroke Scale (NIHSS), which was used to
categorise event severity. Non-disabling events were defined as NIHSS scores of ≤ 3, and disabling events
were those with scores of ≥ 4. Case fatality was defined as death within 30 days of index event. Long-term
institutionalisation was defined as admission into a nursing or residential care home. Patients’ hospital
records from the Oxford Radcliffe Hospitals NHS Trust were reviewed for any accident and emergency visit,
emergency transport, outpatient care visit, day case or hospitalisation from the date of first TIA or stroke
within the OXVASC study period (i.e. index event) and for up to 5 years.
Costs
Long-term institutionalisation was costed as the cost per week in a private nursing home, which in 2013
was £750 per week.32 All hospital care resource use was priced using reference costs for NHS trusts
and NHS trust financial returns for the year 2009.34 These costs were then updated to 2013 prices using
the Hospital and Community Health Services pay and price inflation index.32
Statistical analysis
Nursing/residential care home admission
A Cox proportional hazards model was used to assess the predictors of 6-month admission into a
nursing or residential care home. We only assessed admission within 6 months of first stroke to avoid
over-estimation of costs owing to non-related conditions. The analysis excluded all patients who had died
within 30 days of index event, as no patient with a case fatal event was admitted into a care home in
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OXVASC study. Independent variables included in the analysis were age at time of event; sex; previously
disabled before the event; previous history of MI, angina, TIA, stroke or atrial fibrillation (AF); index event
type (TIA or stroke); index event severity (non-disabling or disabling); and number of recurrent strokes up
to 5 years after the index event (Table 11).
A 6-month risk of admission into a care home in ICSS stroke patients was predicted based on the results
of the regression analyses presented in Table 11. We multiplied this predicted risk by £19,740, which was
the mean 1-year care home cost for a stroke patient admitted within 6 months to a nursing or residential
care home. Given that no OXVASC study patient was admitted into a care home after a case fatal event,
ICSS patients with a fatal event as their first stroke were assigned a cost of £0.
Hospital care
A generalised gamma linear model assuming a log identity was used to determine the predictors of
5-year hospital care costs. Independent variables included in the analysis were: age at time of event; sex;
previously disabled before the event; previous history of each of MI, angina, peripheral vascular disease
(PVD), hypertension, TIA, stroke or atrial fibrillation; index event type (TIA or stroke); index event severity
(non-disabling, disabling, fatal); and, number of recurrent strokes up to 5 years after the index event
(Table 12).
TABLE 11 Predictors of 6-month care home admission
Characteristic HR p-value 95% CI
Age 1.088 < 0.001 1.044 to 1.134
Sex
Female Reference
Male 0.687 0.245 0.365 to 1.293
Previously disabled 3.514 < 0.001 1.866 to 6.620
History of:
MI 0.515 0.212 0.182 to 1.458
TIA 0.319 0.037 0.109 to 0.935
Stroke 0.687 0.460 0.667 to 2.448
Angina 1.222 0.634 0.535 to 2.791
AF 2.567 0.003 1.374 to 4.797
Index event
TIA Reference
Stroke 1.138 0.794 0.432 to 2.996
Index event severity
Non-disabling Reference
Disabling 4.590 < 0.001 2.164 to 9.735
Number of recurrent strokes 1.372 0.149 0.893 to 2.107
Observations 1046
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The 5-year costs estimated using this model were assumed to be distributed across each year using the
proportions reported in Luengo-Fernandez et al.36 We applied these proportions and matched the resulting
cost profile to the stroke patients in the ICSS data set based on the year of follow-up in which the event
occurred, omitting costs that occurred outside the 5-year time horizon of the economic evaluation.
Given that stroke is associated with old age and often occurs in patients with other comorbidities, such
patients are likely to consume substantial health-care resources regardless of event onset. Therefore, the
predicted costs that can be estimated from Table 12 include costs incurred owing to conditions unrelated
to stroke. As a result, to better quantify the impact of stroke on costs, we estimated the pre-morbid
annual costs (i.e. costs before the initial stroke) and subtracted these from the hospital care costs incurred
at each year of follow-up. A similar regression model to that presented in Table 12 was used to estimate
pre-morbid costs each year (Table 13). However, we assumed that all costs associated with a fatal event
were attributable to the initial stroke. The data used in the cost-utility analysis are summarised in Table 14.
The additional results for univariate sensitivity analysis calculated at a maximum willingness to pay for a
QALY of £30,000 are shown in Figure 12. The Consolidated Health Economic Evaluation Reporting
Standards statement is given in Table 15.
TABLE 12 Predictors of hospital care costs after stroke
Predictors Coefficient p-value 95% CI
Age 0.019 < 0.001 0.013 to 0.026
Sex
Female Reference
Male –0.207 0.010 –0.364 to –0.050
Previously disabled 0.229 < 0.001 0.034 to 0.424
History of:
MI 0.037 0.777 –0.220 to 0.294
TIA –0.224 0.036 –0.433 to –0.014
Stroke 0.083 0.388 –0.105 to 0.270
PVD 0.335 0.012 0.734 to 0.598
Angina 0.045 0.708 –0.191 to 0.282
Hypertension 0.017 0.838 –0.144 to 0.177
AF 0.159 0.116 –0.040 to 0.358
Index event
TIA Reference
Stroke 0.203 0.049 0.001 to 0.406
Index event severity
Non-disabling Reference
Disabling 0.676 < 0.001 0.486 to 0.865
Fatal –1.608 < 0.001 –1.912 to –1.304
Number of recurrent strokes 0.309 < 0.001 0.200 to 0.419
Constant 7.988 < 0.001 7.427 to 8.550
Observations 1205
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Summary of data used in cost–utility analysis
TABLE 14 Resource use, costs, utility values and QALYs
Variable
Endarterectomy Stenting
Unit cost/sourceValue (£) N Value (£) N
Procedure duration (minutes),
mean (SD)
107 (47) 700 68 (33) 691
Consultant vascular surgeon, n 1 0 £140 per hour/reference32
Consultant interventional
radiologist, n
0 1 £140 per hour/reference32
Surgical registrar, n 1 0 £59 per hour/reference32
Consultant anaesthetist, na 1 1 £140 per hour/reference32
Theatreb £743 per hour/reference32
TABLE 13 Predictors of hospital care costs in the year before stroke
Predictors Coefficient p-value 95% CI
Age 0.019 0.004 0.006 to 0.032
Sex
Female Reference
Male –0.090 0.590 –0.416 to 0.236
Previously disabled 1.880 < 0.001 1.425 to 2.333
History of:
MI 0.436 0.074 –0.043 to 0.914
TIA 0.150 0.546 –0.337 to 0.637
Stroke –0.091 0.682 –0.528 to 0.345
PVD 0.624 0.041 0.026 to 1.221
Angina 0.591 0.008 0.156 to 1.028
Hypertension –0.099 0.564 –0.436 to 0.238
AF 0.512 0.006 0.144 to 0.880
Index event
TIA Reference
Stroke 0.226 0.169 –0.096 to 0.548
Index event severity
Non-disabling Reference
Disabling 0.253 0.266 –0.192 to 0.698
Constant 4.813 < 0.001 3.769 to 5.856
Observations 1096
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TABLE 14 Resource use, costs, utility values and QALYs (continued )
Variable
Endarterectomy Stenting
Unit cost/sourceValue (£) N Value (£) N
Type of anaesthesia, % 794 853
Local anaesthetic 18 100 £9/reference33
General anaesthetic 82 0 £30/reference33
Shunt used, % 40 818 £38/University College London
Hospitals NHS Foundation Trust
Patch used, % 66 693 £96/University College London
Hospitals NHS Foundation Trust
Stent deployed, % 92 816 £840/University College London
Hospitals NHS Foundation Trust
Cerebral protection device used, % 71 824 £780/University College London
Hospitals NHS Foundation Trust
Other materials used in stentingc £232/University College London
Hospitals NHS Foundation Trust
Admitted to ICU post-operatively, % 64 813 52 808
Length of stay on ICU if admitted
(days)
1 1 £661 per day/reference34
Length of stay on ward (days),
mean (SD)
5.7 (9.4) 803 5.1 (10.8) 789 Endarterectomy £339 per day,
stenting £301 per day/reference34
Additional carotid artery
procedures, mean (SD)
857 853
Endarterectomy 0.039 (0.193) 0.066 (0.257) Mean cost of index procedure
Stenting 0.023 (0.159) 0.028 (0.172) Mean cost of index procedure
Fatal MI in first 30 days, n (%) 0 (0) 857 3 (0.35) 853 £1485/reference35
Non-fatal MI in first 30 days, n (%) 5 (1) 857 0 (0) 853 £5665 in first year, £218 each
year thereafter/reference35
Severe haematoma in first 30 days,
n (%)d
28 (3) 857 8 (1) 853 £9302/reference34
Disabling cranial nerve palsy in first
30 days, n (%)
1 (0) 857 1 (0) 853 £6964/reference34
Imaging tests, ne 857 853
CEMRA 14 13 £208/reference34
CT scan 156 171 £88/reference34
CTA 54 93 £110/reference34
Intra arterial angiography 43 352 £112/reference34
Intravenous DSA 4 16 £150/reference34
MRA 17 23 £157/reference34
MRA/CTA 34 48 £267/reference34
MRI 123 119 £157/reference34
Ultrasound 234 192 £67/reference34
continued
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TABLE 14 Resource use, costs, utility values and QALYs (continued )
Variable
Endarterectomy Stenting
Unit cost/sourceValue (£) N Value (£) N
Drug treatment at 1 month after
treatment, n (%)
785 781
Aspirin 653 (83) 698 (89) £2.57 per month/reference62
Clopidogrel 136 (17) 426 (55) £1.83 per month/reference62
Dipyridamole 161 (21) 94 (12) £5.29 per month/reference62
Antihypertensive 556 (71) 479 (61) £9.61 per month/reference62
Statin 634 (81) 601 (77) £2.12 per month/reference62
Anticoagulant (vitamin K
antagonist)
50 (6) 37 (5) £0.96 per month/reference62
Stroke during 5 year follow-up,
n (%)
71 (8) 857 114 (13) 853
Stroke severity, n (% strokes) 71 114
Non-disabling 26 (37) 70 (61)
Disabling 35 (49) 27 (24)
Fatal 10 (14) 17 (15)
Recurrent strokes, n (% strokes) 71 114
0 62 (87) 102 (89)
1 7 (10) 10 (9)
2 1 (1) 2 (2)
3 1 (1) 0 (0)
Cost per patient of treating
stroke, mean (SD)
71 114
First year 7281 (5627) 5792 (5726) Mean predicted costs/OXVASC
Study
Second year 1398 (1398) 1079 (1628) Mean predicted costs/OXVASC
Study
Third year 2050 (1929) 1602 (2034) Mean predicted costs/OXVASC
Study
Fourth year 1522 (1615) 1178 (1702) Mean predicted costs/OXVASC
Study
Fifth year 1831 (1795) 1426 (1894) Mean predicted costs/OXVASC
Study
Cost of index procedure, mean (SD) 4501 (3570) 586 4724 (3293) 660
Cost of follow-up, mean (SD) 2187 (4522) 389 2401 (5115) 424
Total costs, mean (SD) 6851 (7403) 274 6994 (7913) 340
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TABLE 14 Resource use, costs, utility values and QALYs (continued )
Variable
Endarterectomy Stenting
Unit cost/sourceValue (£) N Value (£) N
Utility values, mean (SD)
Baseline 0.758 (0.231) 846 0.775 (0.212) 841
3 months 0.779 (0.233) 805 0.779 (0.255) 810
6 months 0.768 (0.247) 764 0.759 (0.279) 774
1 year 0.745 (0.272) 775 0.743 (0.296) 777
2 years 0.720 (0.302) 741 0.720 (0.305) 744
3 years 0.685 (0.333) 722 0.675 (0.341) 735
4 years 0.619 (0.361) 589 0.635 (0.363) 620
5 years 0.564 (0.396) 461 0.575 (0.393) 498
QALYs 3.189 (1.204) 329 3.164 (1.364) 362
CEMRA, contrast enhanced magnetic resonance angiography; CTA, computerised tomography angiography; DSA, digital
subtraction angiography; MRA, magnetic resonance angiography.
a The consultant anaesthetist is assumed to spend an additional 30 minutes per patient before and after each procedure.
b Including nursing staff, drugs, consumables and overheads.
c Including catheters, wires and sheaths.
d Requiring surgical evacuation or blood transfusion, or resulting in extended hospital stay.
e Patients may have more than one of each type of test.
Costs are in 2013–14 Great British Pounds (£). All data are raw data with no imputed values.
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Additional results for univariate sensitivity analysis
Base case
Anaesthesia cost: low
Anaesthesia cost: high
Theatre cost: low
Theatre cost: high
Surgeon and radiologist cost: low
Surgeon and radiologist cost: high
Shunt cost: low
Shunt cost: high
Patch cost: low
Patch cost: high
Stent cost: low
Stent cost: high
Cerebral protection device cost: low
Cerebral protection device cost: high
Cost of other materials used in stenting: low
Cost of other materials used in stenting: high
Cost per hospital day: low
Cost per hospital day: high
Cost per additional carotid artery procedures: low
Cost per additional carotid artery procedures: high
Imaging cost: low
Imaging cost: high
Severe haematoma cost: low
Severe haematoma cost: high
Disabling cranial nerve palsy cost: low
Disabling cranial nerve palsy cost: high
Fatal MI cost: low
Fatal MI cost: high
Non-fatal MI cost: low
Non-fatal MI cost: high
Drug treatment cost: low
Drug treatment cost: high
Cost of treating stroke: low
Cost of treating stroke: high
Discount rate: 1.5%
Discount rate: 5%
–4000 –2000 0 2000 4000
Incremental NMB
(maximum willingness to pay for a QALY = £30,000)
FIGURE 12 Univariate sensitivity analysis: results calculated at a maximum willingness to pay for a QALY of
£30,000. All analyses are as for the base-case analysis with univariate adjustment of the parameters listed. Results
are point estimates of the incremental NMB of stenting vs. endarterectomy (circles) and 95% CIs (capped spikes).
The incremental NMB is calculated at a maximum willingness to pay for a QALY of £30,000.
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Consolidated Health Economic Evaluation Reporting Standards statement
TABLE 15 Consolidated Health Economic Evaluation Reporting Standards statement
Section Item number Reported on
Title and abstract
Title 1 The title of Cost–utility analysis of stenting versus endarterectomy for
treatment of symptomatic carotid stenosis identifies the study as an
economic analysis and describes the interventions being evaluated
Abstract 2 A structured summary is provided in the Scientific summary
Introduction
Background and
objectives
3 The broader context for the study, and the research question and its rationale,
are described in Cost–utility analysis of stenting versus endarterectomy for
treatment of symptomatic carotid stenosis
Methods
Target population and
subgroups
4 The target population is described in Chapter 2
Setting and location 5 The setting and location of the trial are described in Chapter 2
Study perspective 6 The study perspective is described in the first part of Cost–utility analysis of
stenting versus endarterectomy for treatment of symptomatic carotid stenosis
Comparators 7 The comparators are described and justified in the first part of Cost–utility
analysis of stenting versus endarterectomy for treatment of symptomatic
carotid stenosis
Time horizon 8 The time horizon is described and justified in the first part of Cost–utility
analysis of stenting versus endarterectomy for treatment of symptomatic
carotid stenosis
Discount rate 9 The discount rate for costs and outcomes is described and justified in the first
part of Cost–utility analysis of stenting versus endarterectomy for treatment
of symptomatic carotid stenosis
Choice of health
outcomes
10 The outcome measure is described and justified in the first part of
Cost–utility analysis of stenting versus endarterectomy for treatment of
symptomatic carotid stenosis
Measurement of
effectiveness
11a The clinical trial used to measure effectiveness is described in Chapter 2
Measurement and
valuation of
preference-based
outcomes
12 Methods used to measure and value preference-based outcomes are
described in the Utilities and QALYs subsection of Cost–utility analysis of
stenting versus endarterectomy for treatment of symptomatic carotid stenosis
Estimating resources
and costs
13a Methods used to estimate resources and costs are described in the Resource
use and costs subsection of Cost–utility analysis of stenting versus
endarterectomy for treatment of symptomatic carotid stenosis
Currency, price date,
and conversion
14 Currency, price date and conversion are described in the first part of
Cost–utility analysis of stenting versus endarterectomy for treatment of
symptomatic carotid stenosis
Choice of model 15 We explain that extrapolation beyond the end of the trial using decision–analytical
modelling was not undertaken in the first part of Cost–utility analysis of stenting
versus endarterectomy for treatment of symptomatic carotid stenosis
Assumptions 16 All assumptions used in the analysis are described throughout Cost–utility
analysis of stenting versus endarterectomy for treatment of symptomatic
carotid stenosis and Appendix 9
Analytical methods 17 Analytical methods are described in the Dealing with missing data and
Statistical methods subsections in Cost–utility analysis of stenting versus
endarterectomy for treatment of symptomatic carotid stenosis
continued
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TABLE 15 Consolidated Health Economic Evaluation Reporting Standards statement (continued )
Section Item number Reported on
Results
Study parameters 18 The main study parameters are in Table 9 in Findings of the cost–utility
analysis and Appendix 9
Incremental costs and
outcomes
19 Incremental costs and outcomes are reported in Tables 9 and 10 and
Appendix 9 and discussed throughout Findings of the cost–utility analysis
Characterising
uncertainty
20a Methods used in the sensitivity analyses are described in the Sensitivity and
subgroup analyses subsection in Cost–utility analysis of stenting versus
endarterectomy for treatment of symptomatic carotid stenosis. The results
are presented in Table 10 and Figures 10 and 11, and discussed in the
Sensitivity and subgroup analyses subsection in Findings of the cost–utility
analysis
Characterising
heterogeneity
21 Methods used in the subgroup are described in the Sensitivity and subgroup
analyses subsection in the Cost–utility analysis of stenting versus
endarterectomy for treatment of symptomatic carotid stenosis. The results
are presented in Table 10 and discussed in the Sensitivity and subgroup
analyses subsection in Findings of the cost–utility analysis
Discussion
Study findings,
limitations,
generalisability and
current knowledge
22 Study findings, limitations, generalisability and comparisons with current
knowledge are discussed in Chapter 4
Other
Source of funding 23 The funding source is in the Acknowledgements. The role of the funder is
described in the Role of the funding source
Conflicts of interest 24 Conflicts of interests are described in the Competing interests
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Appendix 10 International Carotid Stenting Study
investigators and recruiting centres
Steering Committee
A Algra, J Bamford (chairperson), J Beard, M Bland, AW Bradbury, MM Brown (chief investigator),
A Clifton, P Gaines, W Hacke, A Halliday, I Malik, JL Mas, AJ McGuire, P Sidhu and G Venables.
Credentialling Committee
A Bradbury, MM Brown, A Clifton and P Gaines.
Data Monitoring Committee
R Collins, A Molyneux, R Naylor and C Warlow (chairperson).
Outcome Event Adjudication Committee
JM Ferro and D Thomas.
Central office staff at University College London Institute
of Neurology
LH Bonati, L Coward, J Dobson (trial statistician), D Doig, J Ederle, RF Featherstone (trial manager),
F Kennedy, H Tindall, E Turner, DJH McCabe and A Wallis.
Location of International Carotid Stenting Study
recruiting centres
The numbers of patients recruited at each centre (in square brackets) and investigators at each centre are
recorded; PI, local principal investigator.
Australia
Austin Health, Heidelberg [46]: M Brooks, B Chambers (PI), A Chan, P Chu, D Clark, H Dewey,
G Donnan, G Fell, M Hoare, M Molan, A Roberts and N Roberts.
Box Hill Hospital (Monash University), Melbourne [25]: B Beiles, C Bladin (PI), C Clifford, G Fell,
M Grigg and G New.
Monash Medical Centre, Clayton [26]: R Bell, S Bower, W Chong, M Holt, A Saunder and PG Than (PI).
Princess Alexandra Hospital, Brisbane [48]: S Gett, D Leggett, T McGahan (PI), J Quinn, M Ray,
A Wong and P Woodruff.
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Repatriation General Hospital, Daw Park, Adelaide [6]: R Foreman, D Schultz (PI), R Scroop and
B Stanley.
Royal Melbourne Hospital, Melbourne [57]: B Allard, N Atkinson, W Cambell, S Davies (PI), P Field,
P Milne, P Mitchell, B Tress and B Yan.
The Royal Hobart Hospital, Hobart [18]: A Beasley, D Dunbabin, D Stary and S Walker (PI).
Belgium
Antwerp University Hospital, Antwerp [10]: P Cras, O d’Archambeau, JMH Hendriks (PI) and
P Van Schil.
AZ St Blasius, Dendermonde [5]: M Bosiers (PI), K Deloose and E van Buggenhout.
AZ Sint Jan Brugge-Oostende, Campus Brugge, Brugges [18]: J De Letter, V Devos, J Ghekiere and
G Vanhooren (PI).
Cliniques Universitaires St Luc, Bruxelles [1]: P Astarci, F Hammer, V Lacroix, A Peeters (PI) and
R Verhelst.
Imelda Ziekenhuis, Bonheiden [3]: L DeJaegher (PI), A Peeters and J Verbist.
Canada
Centre hospitalier de l’université de Montréal/Notre-Dame Hospital, Montreal [30]: J-F Blair,
JL Caron, N Daneault, M-F Giroux, F Guilbert, S Lanthier, L-H Lebrun, V Oliva, J Raymond, D Roy (PI),
G Soulez and A Weill.
Foothills Medical Centre, Calgary [4]: M Hill (PI), W Hu, M Hudion, W Morrish, G Sutherland and
J Wong.
Finland
Helsinki University Central Hospital, Helsinki [33]: A Albäck, H Harno, P Ijäs, M Kaste (PI),
M Lepäntalo, S Mustanoja, T Paananen, M Porras, J Putaala, M Railo, T Sairanen, L Soinne,
A Vehmas and P Vikatmaa.
Germany
Otto von Guericke University, Magdeburg [9]: M Goertler (PI), Z Halloul and M Skalej.
Ireland
Beaumont Hospital, Dublin [4]: P Brennan, C Kelly, A Leahy, J Moroney (PI) and J Thornton.
New Zealand
Auckland City Hospital, Auckland [40]: PA Barber, R Bourchier, A Hill, A Holden and J Stewart (PI).
Norway
Rikshospitalet University Hospital, Oslo [16]: SJ Bakke (PI), K Krohg-Sørensen, M Skjelland and
B Tennøe.
Poland
Institute of Psychiatry and Neurology (2nd Department of Neurology and Department of
Neuroradiology) and Medical University of Warsaw (2nd Department of General, Vascular and
Oncological Surgery), Warsaw [20]: P Bialek, Z Biejat, W Czepiel, A Czlonkowska (PI), A Dowzenko,
J Jedrzejewska, A Kobayashi, M Lelek and J Polanski.
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Slovenia
University Medical Centre, Ljubljana [12]: J Kirbis, Z Milosevic and B Zvan (PI).
Spain
Hospital Clinic, Barcelona [18]: J Blasco, A Chamorro (PI), J Macho, V Obach, V Riambau and
L San Roman.
Parc Taulí Sabadell Hospital, Barcelona [33]: J Branera, D Canovas (PI), Jordi Estela, A Gimenez Gaibar
and J Perendreu.
Sweden
Malmö University Hospital, Malmö [67]: K Björses, A Gottsater (PI), K Ivancev, T Maetzsch and
B Sonesson.
Sodersjukhuset, Stockholm [55]: B Berg, M Delle, J Formgren, P Gillgren, T-B Kall, P Konrad (PI),
N Nyman and R Takolander.
The Karolinska Institute, Stockholm [5]: T Andersson, J Malmstedt, M Soderman, C Wahlgren and
N Wahlgren (PI).
Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne [12]: S Binaghi, L Hirt, P Michel (PI) and P Ruchat.
University Hospital Basel, Basel [94]: LH Bonati, ST Engelter, F Fluri, L Guerke, AL Jacob, E Kirsch,
PA Lyrer (PI), E-W Radue, P Stierli, M Wasner and S Wetzel.
University Hospital of Geneva, Geneva [16]: C Bonvin, A Kalangos, K Lovblad, N Murith, D Ruefenacht
and R Sztajzel (PI).
The Netherlands
Academic Medical Centre, Amsterdam [56]: M Koelemaij, PJ Nederkoorn (PI), J Reekers and YB Roos.
Erasmus Medical Centre, Rotterdam [75]: JM Hendriks, PJ Koudstaal (PI), PMT Pattynama, A van der Lugt,
LC van Dijk, MRHM van Sambeek, H van Urk and HJM Verhagen.
The Haga Teaching Hospitals, The Hague [45]: CMA Bruijninckx, SF de Bruijn, R Keunen,
B Knippenberg, A Mosch (PI), F Treurniet, L van Dijk, H van Overhagen and J Wever.
Isala Klinieken, Zwolle [14]: FC de Beer, JSP van den Berg (PI), BAAM van Hasselt and DJ Zeilstra.
Medical Centre Haaglanden, The Hague [3]: J Boiten (PI), JCA de Mol van Otterloo, AC de Vries,
GJ Lycklama a Nijeholt and BFW van der Kallen.
UMC St Radboud, Nijmegen [13]: JD Blankensteijn, FE De Leeuw, LJ Schultze Kool (PI) and
JA van der Vliet.
University Medical Centre, Utrecht [270]: GJ de Borst, GAP de Kort, LJ Kapelle (PI), TH Lo,
WPThM Mali, F Moll, HB van der Worp and H Verhagen.
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UK
Addenbrookes Hospital, Cambridge [5]: N Higgins, PJ Kirkpatrick, P Martin (PI) and K Varty.
Birmingham Heartlands Hospital, Birmingham [11]: D Adam, J Bell, AW Bradbury, P Crowe,
M Gannon, MJ Henderson, D Sandler, RA Shinton (PI), JM Scriven and T Wilmink.
Lancashire Teaching Hospitals NHS Trust, Preston [2]: S D’Souza, A Egun, R Guta, S Punekar,
DM Seriki (PI) and G Thomson.
Liverpool Royal Infirmary [21] and The Walton Centre, Liverpool [7]: JA Brennan, TP Enevoldson,
G Gilling-Smith (PI), DA Gould, PL Harris, RG McWilliams, H-C Nasser and R White.
Manchester Royal Infirmary, Manchester [2]: KG Prakash, F Serracino-Inglott, G Subramanian (PI),
JV Symth and MG Walker.
Newcastle Acute Hospitals NHS Foundation Trust, Newcastle-Upon-Tyne [108]: M Clarke, M Davis,
SA Dixit, P Dorman (PI), A Dyker, G Ford, A Golkar, R Jackson, V Jayakrishnan, D Lambert, T Lees, S Louw,
S Macdonald, AD Mendelow, H Rodgers, J Rose, G Stansby and M Wyatt.
North Bristol NHS Trust, Frenchay Hospital, Bristol [13]: T Baker, N Baldwin (PI), L Jones, D Mitchell,
E Munro and M Thornton.
Royal Free Hospital, London [1]: D Baker, N Davis, G Hamilton (PI), D McCabe, A Platts and J Tibballs.
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield [151]: J Beard, T Cleveland, D Dodd,
P Gaines, R Lonsdale, R Nair, A Nassef, S Nawaz and G Venables (PI).
St George’s University of London and St George’s NHS Healthcare Trust, London [58]: A Belli,
A Clifton, G Cloud, A Halliday, H Markus (PI), R McFarland, R Morgan, A Pereira and A Thompson.
St Mary’s Hospital, Imperial College Healthcare NHS Trust, London [13]: J Chataway (PI), N Cheshire,
R Gibbs, M Hammady, M Jenkins, I Malik and J Wolfe.
University College London Hospitals NHS Foundation Trust, London [51]: M Adiseshiah, C Bishop,
S Brew, J Brookes, MM Brown (PI), R Jäger and N Kitchen.
University Hospital of South Manchester, Wythenshawe, Manchester [58]: R Ashleigh, S Butterfield,
GE Gamble, C McCollum (PI), A Nasim, P O’Neill and J Wong.
Western Infirmary, Glasgow [5]: RD Edwards, KR Lees, AJ MacKay, J Moss (PI) and P Rogers.
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